# Maternal plasma cell-free RNA as a predictive test for fetal lung maturation.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12305955</article-id><article-id pub-id-type="pmid">40722151</article-id>
<article-id pub-id-type="publisher-id">4256</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04256-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Maternal plasma cell-free RNA as a predictive test for fetal lung maturation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Carter</surname><given-names>Sean W. D.</given-names></name><address><email>e0983544@u.nus.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Seah</surname><given-names>Kay Yi Michelle</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Poh</surname><given-names>Si En</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Koh</surname><given-names>Winston</given-names></name><address><email>winston_koh@ibb.a-star.edu.sg</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Usuda</surname><given-names>Haruo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Erin L.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kumagai</surname><given-names>Yusaku</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Tsukasa</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Monteiro</surname><given-names>Lara J.</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Pe&#x000f1;ailillo</surname><given-names>Reyna</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Nardocci</surname><given-names>Gino</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Watson</surname><given-names>Hannah R. S.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Saito</surname><given-names>Masatoshi</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Choolani</surname><given-names>Mahesh A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Illanes</surname><given-names>Sebasti&#x000e1;n E.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Kemp</surname><given-names>Matthew W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tgyzw49</institution-id><institution-id institution-id-type="GRID">grid.4280.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2180 6431</institution-id><institution>Department of Obstetrics and Gynaecology, </institution><institution>Yong Loo Lin School of Medicine, National University of Singapore, </institution></institution-wrap>1E Kent Ridge Road NUHS Tower Block, Level 12, Singapore, 119228 Singapore </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/036wvzt09</institution-id><institution-id institution-id-type="GRID">grid.185448.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 0221</institution-id><institution>Institute of Bioengineering and Bioimaging, Agency for Science, Technology and Research, </institution></institution-wrap>31 Biopolis Way, The Nanos, Singapore, #07-01138669 Singapore </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/047272k79</institution-id><institution-id institution-id-type="GRID">grid.1012.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7910</institution-id><institution>Division of Obstetrics and Gynaecology, </institution><institution>University of Western Australia, </institution></institution-wrap>Perth, Australia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00kcd6x60</institution-id><institution-id institution-id-type="GRID">grid.412757.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0641 778X</institution-id><institution>Centre for Perinatal and Neonatal Medicine, </institution><institution>Tohoku University Hospital, </institution></institution-wrap>Sendai, Japan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v0qd864</institution-id><institution-id institution-id-type="GRID">grid.440627.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0487 6659</institution-id><institution>Reproductive Biology Program, Center for Biomedical Research and Innovation, </institution><institution>Universidad de los Andes, </institution></institution-wrap>Santiago, Chile </aff><aff id="Aff6"><label>6</label>IMPACT, Center of Interventional Medicine for Precision and Advanced Cellular Therapy, Santiago, Chile </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v0qd864</institution-id><institution-id institution-id-type="GRID">grid.440627.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0487 6659</institution-id><institution>Faculty of Medicine, </institution><institution>Universidad de los Andes, </institution></institution-wrap>Santiago, Chile </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04fp9fm22</institution-id><institution-id institution-id-type="GRID">grid.412106.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0621 9599</institution-id><institution>Department of Obstetrics and Gynaecology, </institution><institution>National University Hospital, </institution></institution-wrap>Singapore, Singapore </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05tjjsh18</institution-id><institution-id institution-id-type="GRID">grid.410759.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0451 6143</institution-id><institution>Department of Obstetrics and Gynaecology, </institution><institution>National University Centre for Women and Children (NUWoC), National University Health System, </institution></institution-wrap>Singapore, Singapore </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03j1avm36</institution-id><institution-id institution-id-type="GRID">grid.454082.f</institution-id><institution>Women and Infants Research Foundation, </institution></institution-wrap>Perth, WA Australia </aff></contrib-group><pub-date pub-type="epub"><day>28</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>7</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>441</elocation-id><history><date date-type="received"><day>8</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>7</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">A lack of tests to assess fetal development impacts decision making around antenatal steroid use in women at risk of preterm birth. We analyzed the expression of 21 cfRNA targets related to human fetal lung maturation. Discovery studies were performed using maternal and fetal&#x000a0;sheep plasma, with results compared to fetal lung mRNA expression. These findings were&#x000a0;then validated in first, second, and third trimester human maternal plasma samples.</p></sec><sec><title>Methods</title><p id="Par2">Discovery studies utilized a preterm sheep model of pregnancy. Date mated ewes received saline (control <italic>n</italic>&#x02009;=&#x02009;6), or antenatal steroids (dexamethasone <italic>n</italic>&#x02009;=&#x02009;12) (betamethasone <italic>n</italic>&#x02009;=&#x02009;11) prior to delivery and ventilation. We analyzed the expression of 21 human cfRNA targets related to lung maturation in maternal and fetal sheep&#x000a0;plasma and compared this to mRNA expression in fetal lung tissue. Findings were first validated in a separate cohort of sheep exposed to betamethasone (<italic>n</italic>&#x02009;=&#x02009;8), intraamniotic LPS endotoxin for lung maturation (<italic>n</italic>&#x02009;=&#x02009;6), or untreated term animals (<italic>n</italic>&#x02009;=&#x02009;6). Findings were further validated in maternal plasma from a human cohort of uncomplicated term pregnancies (<italic>n</italic>&#x02009;=&#x02009;10). Delivery and ventilation data were analyzed with ANOVA, Tukey HSD, and Dunnett T3 tests. A Random Forest algorithm identified genes that separated mature from immature fetal lung subgroups and determined AUC values for maternal and fetal cell-free RNA (cfRNA) feature sets to predict fetal lung maturation.</p></sec><sec><title>Results</title><p id="Par3">We demonstrate that the analysis of 21 human cfRNA targets in maternal plasma is highly predictive of fetal lung maturation status across antenatal steroid induced (Dexamethasone AUC&#x02009;=&#x02009;0.93; Betamethasone AUC&#x02009;=&#x02009;1) and physiological (AUC&#x02009;=&#x02009;1) lung development models. Maternal plasma cfRNA expression in the dexamethasone antenatal steroid group closely resembled direct fetal lung tissue mRNA expression. These findings were then validated in human maternal plasma samples (1st vs. 3rd trimester AUC&#x02009;=&#x02009;0.96; 2nd vs. 3rd trimester AUC&#x02009;=&#x02009;1).</p></sec><sec><title>Conclusions</title><p id="Par4">Further development of this technology may provide a rapid, minimally invasive, and cost-effective clinical tool to optimize patient selection for initial and repeat courses of antenatal steroids, along with insights into the molecular mechanisms underlying fetal lung development.</p></sec><sec><title>Graphical Abstract</title><p id="Par5">Graphical abstract illustrating the potential future application of maternal plasma cell-free&#x000a0;RNA analysis. Created in <ext-link ext-link-type="uri" xlink:href="https://BioRender.com">https://BioRender.com</ext-link>.</p><p id="Par6">
<graphic position="anchor" xlink:href="12916_2025_4256_Figa_HTML" id="MO1"/></p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04256-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cell-free RNA</kwd><kwd>Preterm birth</kwd><kwd>Lung maturation</kwd><kwd>Antenatal corticosteroids</kwd><kwd>Predictive test</kwd><kwd>Gene expression</kwd><kwd>Minimally invasive</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001104</institution-id><institution>RANZCOG Research Foundation</institution></institution-wrap></funding-source><award-id>Fotheringham Research Fellowship</award-id><principal-award-recipient><name><surname>Carter</surname><given-names>Sean W. D.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Ministry of Education, Government of Singapore</institution></funding-source><award-id>NUHSRO/2021/109/T1/Seed-Sep/02)</award-id><principal-award-recipient><name><surname>Kemp</surname><given-names>Matthew W.</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100020265</institution-id><institution>Stan Perron Charitable Foundation</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001069</institution-id><institution>Women and Infants Research Foundation</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par17">A major historical challenge in perinatal medicine has been the ability to obtain accurate, real-time data on fetal development and wellbeing without relying on invasive procedures or resorting to iatrogenic delivery due to uncertainty about the fetal condition. This limitation has impacted our ability to offer patients robust antenatal screening, early diagnosis, and timely delivery planning for many of the great obstetrical syndromes such as preeclampsia, preterm birth, and intra-uterine growth restriction.</p><p id="Par18">Recent advances in ultrasound imaging have provided improvements in our understanding of anatomical and physiological development, while the advent of cell-free DNA has aided screening for permanent genetic disorders such as aneuploidies. However, there remains no minimally invasive tool for assessing real-time <italic>in utero</italic> fetal gene expression and how the fetal transcriptome evolves with a changing <italic>in utero</italic> environment, advancing fetal development, infection, or disease. Recent advances in cell-free RNA (cfRNA) technology may provide a much needed, minimally invasive window into the <italic>in utero</italic> temporal and dynamic fetal transcriptome allowing new screening tests to provide the patient with more objective information about the status of the fetus, enabling an informed decision about the management of her pregnancy.</p><p id="Par19">One particular area of obstetric practice that would benefit from a real-time cfRNA test of fetal development is in the management of patients at risk of preterm birth (PTB). Preterm birth (delivery before completion of the 37th week of pregnancy) affects 11% of all pregnancies (approximately 15 million births each year) and is the leading cause of death and morbidity worldwide for children under 5&#x000a0;years old [<xref ref-type="bibr" rid="CR1">1</xref>]. Although preterm infants face a host of immediate challenges (especially in low-resource settings), death is frequently related to respiratory complications deriving from being born with functionally immature lungs [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Given this, the primary perinatal strategy for preterm infants focuses on enhancing and supporting the function of their immature lungs.</p><p id="Par20">The antenatal administration of glucocorticoids (either dexamethasone or betamethasone) is a key intervention targeting rapid maturation of the preterm fetal lung. These antenatal steroids (ANS) are routinely administered to women clinically assessed to be at risk of imminent preterm delivery, supported by extensive data demonstrating a reduced risk of perinatal death and/or reduced risk of respiratory morbidity depending on gestational age at delivery [<xref ref-type="bibr" rid="CR4">4</xref>]. Despite these demonstrated benefits, glucocorticoids are potent drugs that exert broad endocrine, physiological and transcriptomic effects, impacts that must be considered when making clinical decisions regarding their administration [<xref ref-type="bibr" rid="CR5">5</xref>]. Current data show that over 70% of preterm births occur in the late preterm gestation (&#x0003e;&#x02009;34&#x000a0;weeks gestation) where the benefits of ANS therapy become increasingly modest [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. Concerningly, up to 50% of women administered ANS (explained by the poor predictive value of the tools available to predict PTB risk) deliver at an extended ANS treatment-to-delivery interval, or at term, scenarios in which both mother and fetus derive little or no benefit from treatment [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par21">Concerningly, there is increasing evidence that ANS exert potentially harmful, off target, adverse effects on the fetus. Reported off-target effects of ANS include lower birthweight and head circumference [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>], neonatal hypoglycemia [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR18">18</xref>], short- and long-term HPA axis and immune system dysregulation (including increased serious neonatal infection and sepsis), increased cardiovascular risk into adulthood (impaired insulin resistance and aortic arch stiffness) [<xref ref-type="bibr" rid="CR19">19</xref>], and increased frequency of neuropsychiatric disorders [<xref ref-type="bibr" rid="CR20">20</xref>] and learning difficulties [<xref ref-type="bibr" rid="CR21">21</xref>]. The few long-term ANS follow-up studies undertaken have reported generally (but not universally) benign findings but are also subject to bias due to high (i.e.,&#x02009;&#x0003e;&#x02009;50%) loss to follow-up rates in the study cohorts [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par22">Therefore, current obstetric practice results in a large number of women and babies being unnecessarily exposed to ANS as they deliver at term or late preterm. This exposure not only negates the intended treatment benefits but also potentially increases the risk of steroid-related harm to both mother and fetus. One key reason many women around the world continue to be exposed to single and repeat courses of ANS therapy to promote fetal lung maturation is that there is no routine test available to predict fetal lung maturation status and thus inform ANS therapy decision making. Legacy diagnostic tests of fetal lung maturation such as lecithin/sphingomyelin ratios, surfactant-to-albumin ratio, or lamina body counts from amniotic fluid require invasive amniocentesis for sample collection and utilize toxic compounds in the laboratory analysis meaning that they are now not commonly available in many clinics [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Aside from cost and resource demands, amniocentesis carries a small risk to both mother and fetus [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], and has limited clinical application in many of the obstetric conditions related to preterm birth as it is often not technically able to be performed. Therefore, clinicians routinely adopt a conservative management approach by administering ANS, wishing to avoid a missed treatment opportunity. Given this, the development of a rapid, scalable, readily available, and minimally invasive, maternal blood test for fetal lung maturation status has the potential to drastically optimize patient selection for ANS by guiding the clinical decision to give or not give ANS to induce lung maturation.</p><p id="Par23">Recent studies have demonstrated that cfRNA analysis of template extracted from maternal plasma constitutes a means of minimally invasive, real-time window into normal and abnormal <italic>in utero</italic> fetal cellular development and function such as pre-eclampsia, gestational age, and preterm birth [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>]. However, no study has yet investigated the use of maternal plasma cfRNA to determine fetal lung maturation status.</p><p id="Par24">In the present study, we used biologically informed human cfRNA targets identified from the analysis of human term and preterm amniotic fluid samples by Whitsett and colleagues [<xref ref-type="bibr" rid="CR31">31</xref>]. We first performed discovery and validation studies in a sheep model of pregnancy before undertaking validation studies in human clinical samples (first, second, and third trimester maternal plasma samples). We subsequently demonstrated that the targeted analysis of cfRNA in the maternal plasma is highly accurate for the prediction of both ANS induced and physiological lung maturation. Further development of this new liquid biopsy has the potential to enhance patient selection for ANS therapy and could also be applied more broadly to monitor fetal organ development or detect disease. This approach offers a novel, real-time window into <italic>in utero</italic> life and development.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par25">This study utilized both secondary and primary plasma samples from sheep studies, findings were then validated in human pregnancy samples. Using a preterm sheep model of pregnancy (allowing for integration of functional lung maturation status and corresponding maternal and fetal plasma cfRNA expression), we aimed to assess the accuracy of targeted maternal plasma cfRNA expression to accurately predict fetal lung maturation status. We explored different interventions of lung maturation including antenatal steroids, physiological (term), and sterile intra-amniotic inflammation (LPS Endotoxin). All animal studies were reviewed and approved by the University of Western Australia&#x02019;s Animal Ethics Committee prior to work commencing (2021/ET000974) / 2022/ET000920) and adhered to the NIH Guide for the Care and Use of Laboratory Animals and the ARRIVE guidelines on the use of laboratory animals.</p><p id="Par26">All discovery and validation sheep studies utilized date mated merino ewes carrying a singleton fetus which were randomly allocated to treatment interventions at 122&#x02009;&#x000b1;&#x02009;2 gestational days (term&#x02009;=&#x02009;150&#x000a0;days). Initial discovery studies utilized secondary analysis of samples from Usuda et al. [<xref ref-type="bibr" rid="CR32">32</xref>] with interventions being IM injections of either:<list list-type="simple"><list-item><label>(i)</label><p id="Par27">4&#x02009;&#x000d7;&#x02009;6&#x000a0;mg Dexamethasone Phosphate 12 hourly (Dexamethasone 48 Hour group) (<italic>n</italic>&#x02009;=&#x02009;12)</p></list-item><list-item><label>(ii)</label><p id="Par28">4&#x02009;&#x000d7;&#x02009;2&#x000a0;ml Saline (Negative Control) (<italic>n</italic>&#x02009;=&#x02009;6)</p></list-item><list-item><label>(iii)</label><p id="Par29">4&#x02009;&#x000d7;&#x02009;2&#x000a0;mg Betamethasone Phosphate 12 hourly (Betamethasone 48 Hour group) (<italic>n</italic>&#x02009;=&#x02009;11)</p></list-item></list></p><p id="Par30">Preterm lambs were delivered via caesarean section&#x000a0;48&#x000a0;h after the first maternal injection depending on the treatment group. Maternal and fetal blood samples (250&#x000a0;&#x000b5;l) for cfRNA extraction were collected at delivery prior to neonatal ventilation. Subsequent fetal cord blood sampling along with respiratory ventilation data was collected at 10-min intervals during a 30-min mechanical ventilation [<xref ref-type="bibr" rid="CR32">32</xref>]. Lambs were defined as having mature lungs and therefore responded to treatment if the PaCO<sub>2</sub> level after 30&#x000a0;min of ventilation was two standard deviations below the mean of the Saline group which is in line with established cutoffs [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par31">Primary discovery and validation studies utilized the same preterm sheep model of pregnancy and ventilation with interventions being injections of either:<list list-type="simple"><list-item><label>(i)</label><p id="Par32">2&#x02009;&#x000d7;&#x02009;0.25&#x000a0;mg/kg intramuscular (IM) Betamethasone Phosphate&#x02009;+&#x02009;Acetate 24 hourly (Betamethasone 8 Day) (<italic>n</italic>&#x02009;=&#x02009;8)</p></list-item><list-item><label>(ii)</label><p id="Par33">1&#x02009;&#x000d7;&#x02009;3.33&#x000a0;mg USS guided intra-amniotic injection of 055:B5 <italic>E.coli</italic> LPS (Cat# L2880, Sigma Aldrich Australia)&#x02009;+&#x02009;1&#x02009;&#x000d7;&#x02009;2&#x000a0;ml IM Saline (LPS Group) (<italic>n</italic>&#x02009;=&#x02009;6)</p></list-item><list-item><label>(iii)</label><p id="Par34">4&#x02009;&#x000d7;&#x02009;2&#x000a0;ml IM Saline (Negative Control) (<italic>n</italic>&#x02009;=&#x02009;6)</p></list-item><list-item><label>(iv)</label><p id="Par35">No treatment (Term Group) delivered at 144&#x000a0;days gestation (<italic>n</italic>&#x02009;=&#x02009;6)</p></list-item></list></p><p id="Par36">Lambs were delivered via caesarean section&#x000a0;8&#x000a0;days after the first maternal injection. With ventilation and sample collection as above. Maternal and fetal blood samples (250&#x000a0;&#x000b5;l) for cfRNA extraction were collected at delivery prior to neonatal ventilation.</p><p id="Par37">Validation studies were conducted on human plasma samples from the 1st, 2nd, and 3rd trimesters from ten uncomplicated pregnancies who delivered at term and whose children had no neonatal respiratory issues indicating adequately mature fetal lungs at birth. Samples were collected at the Gynecology and Obstetrics Department of Hospital Parroquial de San Bernardo, Santiago, Chile. All women enrolled in this study gave written informed consent for the collection of samples and information. This research was approved by the Ethical Scientific Committees of Universidad de los Andes, Chile. Blood samples were collected at 11&#x02013;13 (early), 22&#x02013;24 (mid), and 32&#x02013;34 (late) weeks in citrate BD Vacutainer tubes (BD Biosciences, San Jose, CA, USA), followed by centrifugation at 1500&#x02009;&#x000d7;&#x02009;<italic>g</italic> for 15&#x000a0;min. Plasma fractions were separated and aliquots were stored at&#x02009;&#x02212;&#x02009;80&#x000b0;C until further analysis.</p></sec><sec id="Sec4"><title>Target primer design</title><p id="Par38">Twenty-one RNA targets related to fetal lung maturation were selected based on human term and preterm amniotic fluid analyses by Whitsett and colleagues [<xref ref-type="bibr" rid="CR31">31</xref>]. Briefly, the approach taken in this study was based on the selection of biologically informed cfRNA targets generally related to fetal lung maturation in the human. It is worth emphasizing that this approach differs from unbiased approaches wherein target selection is often independent of biological function and based on statistical analyses or differential gene expression analyses. Primers were designed according to Integrated DNA Technologies Gen1 design and validated to amplify cross-exonic regions by using the UCSC Genome Browser in-silico PCR tool (<ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/">https://genome.ucsc.edu/</ext-link>). See Additional Table 1&#x000a0;for sheep and Additional Table 2&#x000a0;for human gene target primer specifications, respectively. Additional Table&#x000a0;3 illustrates the housekeeping gene target primers for both sheep and human plasma.
</p></sec><sec id="Sec5"><title>Circulating cfRNA extraction</title><p id="Par39">cfRNA was extracted from 250&#x000a0;&#x000b5;l of maternal blood (sheep and human samples) and fetal blood (sheep samples only) utilizing plasma/serum circulating and Exosomal RNA Purification Kit (Norgen Ontario, Canada; Cat no. 42800). Residual DNA&#x000a0;was digested with a RNase-Free DNase kit (Norgen, Cat no. 25720) and the RNA purified (Zymo Kit, Irvine, CA; Cat no. ZYR. R1016) yielding 20 &#x003bc;L of cfRNA per sample.</p></sec><sec id="Sec6"><title>Reverse transcription and emulsion-based targeted pre-amplification</title><p id="Par40">10 &#x003bc;L of extracted cfRNA was annealed with a final concentration of 0.4&#x000a0;&#x003bc;M of pooled reverse primer mix in the presence of 10<sup>5</sup> copies of luciferase control RNA (Promega, Cat no. L4561) and a final concentration 2&#x000a0;mM of dNTPs at 65&#x000b0;C for 5&#x000a0;min. Reverse transcription of cfRNA was performed using Superscript&#x02122; III Reverse Transcriptase (Thermo Fisher Scientific, Waltham, MA; Cat no. 18080044) at 25&#x000b0;C for 5&#x000a0;min, 50&#x000b0;C for 50&#x000a0;min, and enzyme inactivation at 95&#x000b0;C for 3&#x000a0;min.</p><p id="Par41">cDNA from reverse transcription was added to a PCR mixture comprised of Platinum&#x02122; Taq DNA Polymerase (Thermo Fisher Scientific; Cat no. 10966) with a final concentration of 0.5&#x000a0;&#x003bc;M of rh PCR primer mix and 26&#x000a0;mU of RNase H2 enzyme. An emulsion was generated by adding three parts of 10% 008-FluoroSurfactant (RAN Biotechnologies, Beverley, MA) in 3&#x000a0;M Fluorinert&#x02122; Engineered Fluid (3&#x000a0;M, Saint Paul, MN; Cat no. FC-40) to one part of PCR reaction mixture. The mixture was shaken using a sharp flicking motion for 30&#x000a0;s, until it became cloudy and uniform. Thermocycling started with enzyme activation at 94&#x000b0;C for 2&#x000a0;min, followed by 20 cycles of denaturation (94&#x000b0;C, 15&#x000a0;s), annealing (55&#x000b0;C, 30&#x000a0;s), and extension (68&#x000b0;C, 1&#x000a0;min). Reaction mixtures were frozen overnight at&#x02009;&#x02212;&#x02009;75&#x000b0;C to release PCR products from emulsions. Samples were defrosted at room temperature and the aqueous phase removed. Reactions recovered from the emulsion PCR was topped up with the same amount of polymerase and RNase H2 used in the emulsion PCR. Thermocycling commenced with enzyme activation at 94&#x000b0;C for 2&#x000a0;min, followed by 20 cycles of denaturation (94&#x000b0;C, 15&#x000a0;s), hybridization (78&#x000b0;C, 10&#x000a0;min), annealing (55&#x000b0;C, 30&#x000a0;s), and extension (68&#x000b0;C, 1&#x000a0;min).</p></sec><sec id="Sec7"><title>Quantification of pre-amplified gene targets Using qPCR</title><p id="Par42">qPCR was performed for 60 cycles with Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher, Cat no. K0221). One microliter of the amplified target, 0.3&#x000a0;&#x003bc;M of the forward and reverse primers are added to 12.5&#x000a0;&#x003bc;l of the master mix. Water was then added to form a total 25&#x000a0;&#x003bc;l reaction volume. The mix was then run using a 96-well QuantStudio&#x02122; 3 quantitative PCR cycler (Thermo Fisher Scientific) using the following thermal profile: 95&#x000b0;C for 10&#x000a0;min for the initial denaturation, followed by 60 cycles of 95&#x000b0;C denaturation (15&#x000a0;s) and 65&#x000b0;C annealing and extension (60&#x000a0;s). SYBR Green / ROX Quantification was performed at the end of each extension cycle. Melt curve analysis was performed by ramping the temperature to 95&#x000b0;C (0.3&#x000b0;C / second) after the qPCR run completed to verify the specificity of each PCR product.</p></sec><sec id="Sec8"><title>Sheep lung tissue mRNA extraction</title><p id="Par43">RNA was extracted from frozen lung tissue (right lower lobe) using a Precellys Evolution Cryolys (Bertin Technologies, Ile-de-France, France) programmed as follows: single cycle, 6000&#x000a0;rpm, 5&#x000a0;s, 4&#x000b0;C. Tissue lysates were processed using an RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer&#x02019;s instructions. The concentration and integrity of extracted RNA was determined using an RNA 6000 Nano Kit and measured on a 2100 Bioanalyser system (both Agilent Technologies, Inc., Santa Clara, CA). All RNA extracts had an RIN value&#x02009;&#x0003e;&#x02009;8 and were diluted in nuclease-free water (Life Technologies) to yield a final RNA concentration of 25&#x000a0;ng/&#x003bc;L.</p><p id="Par44">qPCR was performed using cycles with Maxima SYBR Green/ROX qPCR Master Mix (Thermo Fisher, Cat no. K0221). One microliter of the amplified target, 0.3&#x000a0;&#x003bc;M of the forward and reverse primers are added to 12.5&#x000a0;&#x003bc;l of the master mix. Water was then added to form a total 25&#x000a0;&#x003bc;l reaction volume. The mix was then run using a 96 well QuantStudio&#x02122; 3 quantitative PCR cycler (Thermo Fisher Scientific) using the following thermal profile: 95&#x000b0;C for 10&#x000a0;min for the initial denaturation, followed by 60 cycles of 95&#x000b0;C denaturation (15&#x000a0;s) and 65&#x000b0;C annealing and extension (60&#x000a0;s). SYBR Green / ROX Quantification was performed at the end of each extension cycle. Melt curve analysis was performed by ramping the temperature to 95&#x000b0;C (0.3&#x000b0;C / second) after the qPCR run completed to verify the specificity of each PCR product fetal lung mRNA transcripts corresponding to the top 5 RNA targets in maternal and fetal plasma were measured, using the same primers and SYBR chemistry with identical cycling parameters. Delta quantification cycle values were used to determine relative expression of transcripts for statistical analyses. Final data were expressed graphically as fold increase compared to Saline Control Group value.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par45">Statistical analysis was performed using IBM SPSS Statistics for Windows Version 28.0.1.0 (142). Delivery data were tested for significance with <italic>t</italic> tests or ANOVA followed by Tukey HSD, Dunnett t (2-sided), and Dunnett T3 post hoc analysis for multiple comparisons. <italic>P</italic> values less than 0.05 were taken as significant.</p></sec><sec id="Sec10"><title>Data analysis</title><p id="Par46">cfRNA target qPCR cycle threshold (Ct) values were normalized to luciferase calibrator followed by standard delta-delta-Ct normalization using the geometric mean of the three reference genes (GAPDH, RPS18, Beta Actin). Normalized Ct values for each target were used as features for classification. Random Forest algorithm from the Random Forest library in R used to identify genes that separate the animals with mature lungs from animals with immature lungs [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. We further employed the Random Forest method to determine the area under the receiver operating characteristic curve (AUC) for the feature sets [<xref ref-type="bibr" rid="CR39">39</xref>].</p></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Targeted analysis of maternal plasma cfRNA is highly predictive of dexamethasone (antenatal steroid) induced fetal lung maturation in sheep</title><p id="Par47">For the initial discovery study, we undertook secondary analysis of plasma samples collected in a study described by Usuda et al. [<xref ref-type="bibr" rid="CR32">32</xref>]. Date-mated pregnant ewes were administered intramuscular injections (as per clinical practice) of dexamethasone phosphate to induce fetal lung maturation. Saline injections served as a placebo. Lambs were surgically delivered preterm (~&#x02009;equivalent 32/40&#x000a0;weeks gestation) 48&#x000a0;h after treatment and ventilated for 30&#x000a0;min to distinguish those lambs with mature lungs from those with immature lungs (based on established physiological criteria including cord PaCO<sub>2</sub> and ventilation data [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). cfRNA extracted from both maternal and fetal plasma (250&#x000a0;&#x000b5;l per sample) collected at delivery underwent reverse transcription to cDNA with targeted (21 gene targets related to lung maturation) emulsion-based amplification, qPCR, and analysis (Random Forrest Classifier). Maternal plasma cfRNA expression (complete 21 targets) accurately discriminated those ewes carrying a fetus with dexamethasone induced fetal lung maturation (ANS responder) from those ewes&#x02019; carrying a fetus who failed to respond to ANS treatment and had immature lungs (ANS non-responder) mean AUC of 0.82 (95% CI 0.78&#x02013;0.85) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Specific gene targets contributed differently to the accuracy of fetal lung maturation prediction depending on the maternal or fetal plasma analyzed. In maternal plasma, the top 5 of 21 gene targets <italic>SFTPC</italic>, <italic>CTSH</italic>, <italic>AQP5</italic>, <italic>SFTPA1</italic>, and <italic>HOXA5</italic> were of particular importance for fetal lung maturation prediction. When these top five targets were analyzed in isolation, the tests predictive power for fetal lung maturation status was increased to a mean AUC of 0.93 (95% CI 0.93&#x02013;0.94) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p><bold>A</bold> Preterm lamb 30-min ventilation outcomes: Umbilical Arterial pH, PaCO<sub>2</sub>, Dynamic Compliance, and Ventilation Efficiency Index (VEI) for Dexamethasone Groups (Responder&#x02014;mature lung, Non-responder&#x02014;immature lung and Saline control. <bold>B</bold> Dexamethasone Group Maternal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets. <bold>C</bold> Dexamethasone Group Maternal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for top 5 cfRNA targets</p></caption><graphic xlink:href="12916_2025_4256_Fig1_HTML" id="MO2"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Summary of the predictive accuracy of targeted cfRNA expression in maternal and fetal plasma with different lung maturation exposures in sheep and human samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">AUC [95% CI]</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">PPV</th><th align="left">NPV</th></tr></thead><tbody><tr><td align="left"><p>Sheep Maternal</p><p>Dexamethasone 48-h</p></td><td align="left"><p>0.82</p><p>(0.78&#x02013;0.85)</p></td><td align="left">60%</td><td align="left">70%</td><td align="left">0.98</td><td align="left">0.63</td></tr><tr><td align="left"><p>Sheep Maternal</p><p>Dexamethasone Top 5 Targets</p><p>(<italic>SFTPC</italic>, <italic>CTSH, AQP5</italic>, <italic>SFTPA1</italic>, <italic>HOXA5</italic>)</p></td><td align="left"><p>0.93</p><p>(0.93&#x02013;0.94)</p></td><td align="left">64%</td><td align="left">77%</td><td align="left">1</td><td align="left">0.86</td></tr><tr><td align="left"><p>Sheep Fetal</p><p>Dexamethasone 48-h</p></td><td align="left"><p>0.74</p><p>(0.69&#x02013;0.78)</p></td><td align="left">58%</td><td align="left">65%</td><td align="left">0.89</td><td align="left">0.7</td></tr><tr><td align="left"><p>Sheep Fetal</p><p>Dexamethasone Top 5 Targets</p><p>(<italic>NKX2-1</italic>, <italic>HOXA2</italic>, <italic>SFTPD</italic>, <italic>VEGFA, PTGS2</italic>)</p></td><td align="left"><p>0.90</p><p>(0.90&#x02013;0.90)</p></td><td align="left">63%</td><td align="left">75%</td><td align="left">0.92</td><td align="left">0.82</td></tr><tr><td align="left"><p>Sheep Maternal</p><p>Betamethasone 48-h</p></td><td align="left"><p>1</p><p>(1&#x02013;1)</p></td><td align="left">100%</td><td align="left">100%</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left">Sheep Fetal Betamethasone 48-h</td><td align="left"><p>0.93</p><p>(0.78&#x02013;1)</p></td><td align="left">83%</td><td align="left">100%</td><td align="left">1</td><td align="left">0.83</td></tr><tr><td align="left">Sheep Maternal 8-day Betamethasone</td><td align="left"><p>0.80</p><p>(0.41&#x02013;1)</p></td><td align="left">80%</td><td align="left">100%</td><td align="left">1</td><td align="left">0.75</td></tr><tr><td align="left">Sheep Fetal 8-day Betamethasone</td><td align="left"><p>0.75</p><p>(0.26&#x02013;1)</p></td><td align="left">75%</td><td align="left">100%</td><td align="left">1</td><td align="left">0.67</td></tr><tr><td align="left">Sheep Maternal Term</td><td align="left"><p>1</p><p>(1&#x02013;1)</p></td><td align="left">100%</td><td align="left">100%</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left">Sheep Fetal Term</td><td align="left"><p>0.92</p><p>(0.77&#x02013;1)</p></td><td align="left">83%</td><td align="left">90%</td><td align="left">0.83</td><td align="left">0.90</td></tr><tr><td align="left">Human 1st vs 2nd Trimester</td><td align="left"><p>0.95</p><p>(0.85&#x02013;1)</p></td><td align="left">90%</td><td align="left">100%</td><td align="left">1</td><td align="left">0.91</td></tr><tr><td align="left">Human 1st vs 3rd Trimester</td><td align="left"><p>0.96</p><p>(0.89&#x02013;1)</p></td><td align="left">90%</td><td align="left">1</td><td align="left">1</td><td align="left">0.91</td></tr><tr><td align="left">Human 2nd vs 3rd Trimester</td><td align="left"><p>1</p><p>(1&#x02013;1)</p></td><td align="left">100%</td><td align="left">100%</td><td align="left">1</td><td align="left">1</td></tr></tbody></table></table-wrap></p><p id="Par48">For comparison, fetal plasma cfRNA expression was analyzed and interestingly was found to be less accurate for the prediction of fetal lung maturation status mean AUC of 0.74 (95% CI 0.69&#x02013;0.78) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The top 5 of 21 gene targets of importance for the prediction of lung maturation in fetal plasma samples were <italic>NKX2-1</italic>, <italic>HOXA2</italic>, <italic>SFTPD</italic>, <italic>VEGFA</italic>, and <italic>PTGS2</italic>, which when analyzed in isolation generated an AUC of 0.90 (95% CI 0.90&#x02013;0.90) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p><bold>A</bold> Dexamethasone group fetal plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets. <bold>B</bold> Dexamethasone Group Fetal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for top 5 cfRNA targets</p></caption><graphic xlink:href="12916_2025_4256_Fig2_HTML" id="MO3"/></fig></p></sec><sec id="Sec13"><title>Maternal plasma cfRNA expression reflects the fetal lung tissue mRNA expression related to lung maturation</title><p id="Par49">In order to assess if the cfRNA signatures in maternal and fetal plasma correlated to the fetal lung tissue transcriptome, we analyzed the mRNA expression of the top five gene targets from both maternal and fetal plasma cfRNA in fetal lung tissue. We compared lung mRNA from lambs with steroid induced lung maturation (ANS Responder) to saline control (immature lungs) and steroid exposed lambs with immature lungs (ANS Non-responder). We observed significant upregulation of the targets <italic>SFTPC</italic> (mean difference&#x02009;&#x02212;&#x02009;1.63, [95% CI&#x02009;&#x02212;&#x02009;2.46 to&#x02009;&#x02212;&#x02009;0.79], <italic>p</italic>&#x02009;=&#x02009;0.002), <italic>CTSH</italic> (mean difference&#x02009;&#x02212;&#x02009;1.96, [95% CI&#x02009;&#x02212;&#x02009;2.55 to&#x02009;&#x02212;&#x02009;1.36], <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), and <italic>SFTPA1</italic> (mean difference&#x02009;&#x02212;&#x02009;2.25 [95% CI&#x02009;&#x02212;&#x02009;3.62 to&#x02009;&#x02212;&#x02009;0.87], <italic>p</italic>&#x02009;=&#x02009;0.005) in lambs with mature lungs compared to saline control (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A).&#x000a0;These targets corresponded to three of the top five maternal plasma cfRNA targets (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C). In contrast we observed no significant difference in fetal lung tissue mRNA expression of any of the top five fetal plasma cfRNA targets being <italic>NKX21</italic>, <italic>HOXA2</italic>, <italic>SFTPD</italic>, <italic>VEGFA</italic>, or <italic>PTGS2</italic> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). Interestingly, these findings suggest that fetal lung tissue mRNA expression related to lung maturation, closely resembles the cfRNA signature found in maternal plasma but not fetal plasma.<fig id="Fig3"><label>Fig. 3</label><caption><p><bold>A</bold> Dexamethasone Group mRNA quantification from fetal lung tissue in fold change relative to Saline Control Group for Dexamethasone Responder (mature lung) and Non-responder (immature lung) groups. Relative expression of mRNA transcript for the top 5 maternal plasma cfRNA gene targets SFTPC, AQP5, CTSH, SFTPA1, HOXA5. <bold>B</bold> Dexamethasone Group mRNA quantification from fetal lung tissue in fold change relative to Saline Control Group for Dexamethasone Responder (mature lung) and Non-responder (immature lung). Relative expression of mRNA transcript for and the top 5 fetal plasma gene targets NKX2-1, HOXA2, SFTPD, VEGFA, and PTGS2</p></caption><graphic xlink:href="12916_2025_4256_Fig3_HTML" id="MO4"/></fig></p></sec><sec id="Sec14"><title>Validating maternal plasma cfRNA for the prediction of fetal lung maturation in a separate cohort exposed to a betamethasone (antenatal steroid) regimen in sheep</title><p id="Par50">In order to validate our initial discovery findings in a separate cohort of sheep exposed to a different ANS therapy, we undertook secondary analysis of a set of plasma samples from Usuda et al. in lambs exposed to betamethasone. In many parts of the world, betamethasone and dexamethasone are used interchangeably for ANS therapy, despite possessing pronounced differences in pharmacokinetic profiles and glucocorticoid receptor affinity [<xref ref-type="bibr" rid="CR43">43</xref>]. As with the&#x000a0;initial discovery cohort, lambs were surgically delivered preterm (equivalent 32/40&#x000a0;weeks gestation) 48&#x000a0;h after treatment and ventilated for 30&#x000a0;min to distinguish those lambs with mature lungs from those with immature lungs [<xref ref-type="bibr" rid="CR32">32</xref>]. In the betamethasone exposed cohort, analysis of maternal plasma cfRNA expression using the same 21 targets employed in the dexamethasone discovery cohort had an AUC of 1 (95% CI 1&#x02013;1) for the prediction of fetal lung maturation (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). In comparison, cfRNA in fetal plasma had an AUC of 0.93 (95% CI 0.78&#x02013;1) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Interestingly, the top five gene targets in the maternal plasma cfRNA analysis that were most important to the predictive accuracy of the test were <italic>MAPK3</italic>, <italic>VEGFA</italic>, <italic>SFTPC</italic>, <italic>ABCA3</italic>, and <italic>PTGS2</italic> by comparison in the fetal plasma the top five targets of most importance for lung maturation prediction were <italic>PTGS2</italic>, <italic>SFTPB</italic>, <italic>HSPB1</italic>, <italic>SFTPD</italic>, and <italic>HOXA5.</italic> These provide further evidence of the accuracy of maternal cfRNA in predicting steroid induced fetal lung maturation utilizing one of the most widely used ANS regimens in clinical practice worldwide. Interestingly, we observed differences in the cfRNA signatures between dexamethasone and betamethasone, potentially indicating that dexamethasone and betamethasone elicit different maturation effects on the fetus or differentially impact placental release of cfRNA into maternal plasma.<fig id="Fig4"><label>Fig. 4</label><caption><p><bold>A</bold> Betamethasone 48-h Group Maternal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets. <bold>B</bold> Betamethasone 48-h Group Fetal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets</p></caption><graphic xlink:href="12916_2025_4256_Fig4_HTML" id="MO5"/></fig></p></sec><sec id="Sec15"><title>cfRNA is predictive of fetal lung maturation at least 8&#x000a0;days after antenatal steroid administration</title><p id="Par51">To understand if cfRNA changes in maternal plasma remained predictive of fetal lung maturation beyond 48&#x000a0;h after antenatal steroid administration, we performed a primary analysis on maternal and fetal plasma samples from pregnant ewes administered antenatal betamethasone with caesarean section delivery of the preterm lamb (~&#x02009;32&#x000a0;weeks gestation in humans) 8&#x000a0;days after administration. As with the earlier cohorts, lambs were surgically delivered and ventilated for 30&#x000a0;min to allow discrimination of lung maturation status. Analysis of the same of 21 target cfRNA panel was performed. In this cohort, maternal plasma cfRNA had an AUC of 0.8 (95% CI 0.41&#x02013;1) with the top five gene targets of importance to prediction being <italic>SFTPB</italic>, <italic>FOXA2</italic>, <italic>SFTPC</italic>, <italic>SFTPA1</italic>, and <italic>HPSB1</italic> (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Fetal plasma cfRNA had an AUC 0.75 (95% CI 0.26&#x02013;1) with <italic>HOXA2</italic>, <italic>MAPK3</italic>, <italic>PTGS2</italic>, <italic>VEGFA</italic>, and <italic>LPCAT1</italic> being the most important targets to lung maturation prediction (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). These data suggest that plasma cfRNA remains highly predictive over a week after fetal lung maturation has been initiated by antenatal steroids, thereby adding validity and translational value to this predictive test for application in clinical practice.<fig id="Fig5"><label>Fig. 5</label><caption><p><bold>A</bold> Betamethasone 8 Day Group Maternal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets. <bold>B</bold> Betamethasone 8 Day Group Fetal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets</p></caption><graphic xlink:href="12916_2025_4256_Fig5_HTML" id="MO6"/></fig></p></sec><sec id="Sec16"><title>Maternal plasma cfRNA expression is highly accurate for the prediction of physiological fetal lung maturation in a sheep model</title><p id="Par52">Next, in order to assess whether the targeted panel we developed was predictive of physiological lung maturation (as opposed to ANS-induced lung maturation), we undertook a primary analysis comparing maternal and fetal plasma cfRNA expression from a cohort of preterm lambs delivered at 125d GA (equivalent to 32&#x000a0;weeks&#x02019; gestation in humans) to a cohort of lambs delivered at term 144d GA (full-term gestation 150d GA in sheep). Maternal plasma cfRNA expression of the same 21 targets had an AUC 1 (95% CI 1&#x02013;1) for the prediction of fetal lung maturation (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The top five most important targets for prediction being <italic>PIK3R3</italic>, <italic>HOXA5</italic>, <italic>AKT1</italic>, <italic>FOXA2</italic>, and <italic>LYZ</italic> (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>A, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). In comparison, the fetal plasma from this cohort had an AUC 0.92 (95% CI 0.77&#x02013;1) with <italic>NKX21</italic>, <italic>PTGS2</italic>, <italic>SFTPD</italic>, <italic>ABCA3</italic>, and <italic>VEGFA</italic> being the most important targets to prediction (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>B, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig6"><label>Fig. 6</label><caption><p><bold>A</bold> Term Group Maternal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets. <bold>B</bold> Term Group Fetal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets. <bold>C</bold> LPS Group Maternal Plasma GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets</p></caption><graphic xlink:href="12916_2025_4256_Fig6_HTML" id="MO7"/></fig></p></sec><sec id="Sec17"><title>The targeted analysis of maternal plasma cfRNA expression is highly specific for the prediction of steroid and physiological but not inflammation-induced lung maturation</title><p id="Par53"><italic>In utero</italic> inflammation associated with such conditions as chorioamnionitis is known to induce fetal lung maturation [<xref ref-type="bibr" rid="CR44">44</xref>]. In order to assess whether maternal cfRNA expression could also predict inflammation induced fetal lung maturation we administered 3.33&#x000a0;mg of intrauterine lipopolysaccharides (LPS) under ultrasound guidance to pregnant ewes and then delivered the preterm lambs 8&#x000a0;days later at 124d GA. Lambs were ventilated for 30&#x000a0;min to assess lung maturation&#x000a0;status. In comparison to preterm saline control animals, all lambs exposed to LPS had a robust, statistically significant lung maturation response. Interestingly, when comparing LPS to saline control, analysis of maternal plasma cfRNA using our 21-target panel did not allow for accurate prediction of inflammation induced fetal lung maturation, with an AUC of 0.60 (95% CI 0.23&#x02013;0.96) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>C). These findings suggest that there may be temporally and quantitatively different signalling processes between inflammation-induced lung maturation and steroid/physiological lung maturation. Therefore, the cfRNA panel utilized in this study appears specific for the prediction of steroid and physiological lung maturation but not inflammation-induced lung maturation.</p></sec><sec id="Sec18"><title>Validation of cfRNA for the prediction of fetal lung maturation in human plasma samples</title><p id="Par54">In order to validate our findings from sheep studies in a human cohort, we analyzed the same 21 cfRNA targets in human maternal plasma from uncomplicated pregnancies. All babies were delivered at term with no neonatal respiratory compromise at delivery, reflecting a mature fetal lung. Human patient demographics are outlined in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. We compared cfRNA expression in maternal plasma samples collected during the 1st, 2nd, and 3rd trimesters in all patients. Our data showed that 1st compared to 2nd trimester maternal plasma cfRNA expression had an AUC of 0.95 (95% CI 0.85&#x02013;1) with the most important targets being <italic>SFTPB</italic>, <italic>SCNN1B</italic>, <italic>SFTPD</italic>, <italic>SFTPC</italic>, and <italic>FOXA2</italic> (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). 1st compared to 3rd trimester cfRNA expression had an AUC of 0.96 (95% CI 0.89&#x02013;1) with <italic>SFTPB</italic>, <italic>SFTPC</italic>, <italic>AQP5</italic>, <italic>SCNN1B</italic>, and <italic>NKX2-1</italic> contributing the most predictive power (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>B, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Finally, 2nd compared to 3rd trimester maternal cfRNA demonstrated a perfect accuracy of AUC 1 (95% CI 1&#x02013;1) and <italic>FOXA2</italic>, <italic>AQP5</italic>, <italic>MAPK3</italic>, <italic>LPCAT1</italic>, and <italic>SFTPB</italic> being the most important targets to prediction (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>C, Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Fetal samples were not available for analysis.<fig id="Fig7"><label>Fig. 7</label><caption><p><bold>A</bold> Human Plasma 1st vs 2nd Trimester GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets. <bold>B</bold> Human Plasma 1st vs 3rd Trimester GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets. <bold>C</bold> Human Plasma 2nd vs 3rd GINI graph of cfRNA gene targets of variable importance &#x00026; Receiver Operating Characteristics Curve for entire panel of 21 cfRNA targets</p></caption><graphic xlink:href="12916_2025_4256_Fig7_HTML" id="MO8"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Summary of&#x000a0;patient demographics of human plasma sample cohort (mean&#x02009;&#x000b1;&#x02009;standard deviation)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Control Mean (SD) (<italic>n</italic>&#x02009;=&#x02009;10)</th></tr></thead><tbody><tr><td align="left"><bold>Maternal age (years)</bold></td><td align="left">24.4&#x02009;&#x000b1;&#x02009;6.5</td></tr><tr><td align="left"><bold>BMI at 11&#x02013;14&#x000a0;weeks (kg/m</bold><sup><bold>2</bold></sup><bold>)</bold></td><td align="left">28.3&#x02009;&#x000b1;&#x02009;7.8</td></tr><tr><td align="left"><bold>Parity</bold></td><td align="left">0.8&#x02009;&#x000b1;&#x02009;1</td></tr><tr><td align="left"><bold>Gravida</bold></td><td align="left">2.3&#x02009;&#x000b1;&#x02009;1.5</td></tr><tr><td align="left"><bold>Fasting plasma glucose (mg/dL)</bold></td><td align="left">72.7&#x02009;&#x000b1;&#x02009;11.7</td></tr><tr><td align="left"><bold>Smoker</bold></td><td align="left">1/10</td></tr><tr><td align="left"><bold>Illicit drug use</bold></td><td align="left">0</td></tr><tr><td align="left"><bold>Gestational age at delivery</bold></td><td align="left">39.6&#x02009;&#x000b1;&#x02009;0.8</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec19"><title>Discussion</title><sec id="Sec20"><title>Principal findings</title><p id="Par55">The absence of reliable clinical tests to assess fetal lung maturation in women at risk of preterm birth has likely contributed to the widespread and potentially harmful overuse of ANS. In this proof of principle study, we have demonstrated that targeted analysis of cfRNA in maternal plasma enables highly accurate prediction of fetal lung maturation both in the context of antenatal steroid-induced maturation and natural physiological lung development. These findings advance our understanding of temporal, real-time, <italic>in utero</italic> fetal gene expression corresponding to specific organ maturation. The results of this study have the potential to form the basis of a clinical test to optimize and personalize patient selection for antenatal steroid therapy to those women carrying a fetus with immature lungs. Additionally, this analytical tool may be deployed to assist in developing new lead insights into the transcriptional signature and molecular events critical to fetal lung maturation based on the discrete cfRNA signals between maternal and fetal samples.</p><p id="Par56">We report that, in the sheep model of preterm pregnancy, a panel of twenty-one maternal plasma cfRNA targets accurately predicted steroid induced fetal lung maturation in the setting of both dexamethasone (AUC 0.82) and betamethasone (AUC 1) antenatal steroid administration. When the top five maternal gene targets from the dexamethasone group were analyzed in isolation, the test accuracy was improved, yielding an AUC value of 0.93. As the top five cfRNA targets in the maternal compartment accounted for the majority of predictive power of the test, there is significant scope to eliminate most of the original twenty-one target transcripts measured, allowing for improved model performance and streamlining (i.e., faster throughput at lower cost) in any putative clinical application of this approach. Furthermore, we demonstrated that the predictive accuracy of this test remains robust for extended periods of time, up to at least 8&#x000a0;days after betamethasone steroid administration (AUC 0.80). Interestingly, maternal plasma provides better discrimination of fetal lung maturation than the same panel of cfRNA targets in fetal plasma for all steroid-induced fetal lung maturation models. These findings demonstrate that cfRNA in maternal plasma may serve as a useful, minimally invasive tool to inform clinicians on patient selection for repeat courses of ANS in women who remain at risk of preterm birth after the initial course of ANS, as this test is able to accurately predict those fetuses that have responded to ANS treatment with lung maturation from those that have not.</p><p id="Par57">Secondly, we demonstrate that cfRNA in maternal plasma is highly accurate for the prediction of physiological lung maturation in both sheep (AUC 1.0) and human maternal plasma samples. Specifically, the expression of cfRNA in human maternal plasma was highly accurate at predicting lung maturation comparing 1st to 3rd trimester expression (AUC 0.96), 1st compared to 2nd trimester expression (AUC 0.95) and 2nd compared to 3rd trimesters expression (AUC 1.0). This is an important finding as with further development, this test may be applied in personalizing patient selection for initial administration of antenatal steroids in women at risk of preterm birth to those carrying a fetus with immature lungs. This is particularly so for women over 34&#x000a0;weeks&#x02019; gestation where the number needed to treat for ANS to prevent preterm respiratory morbidity drastically increases due to advancing physiological fetal lung maturation [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par58">Interestingly, when we assessed the ability of maternal plasma cfRNA to predict inflammation induced fetal lung maturation, the accuracy of the test was poor (AUC 0.60). As the cfRNA targets chosen were based on gene expression in amniotic fluid related to physiological lung maturation, our findings indicate that inflammation-induced lung maturation may exhibit a distinctly different molecular and transcriptional profile to both steroid induced and physiological lung maturation. This observation is understandable given earlier work by ourselves, and others, showing that although both intrauterine endotoxin exposure and glucocorticoid exposure elicit fetal lung maturation in the sheep, the maturation processes these agent induce occur over quite distinct time scales [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]; functional maturation responses from glucocorticoids are evident after 48&#x000a0;h in the sheep, but take longer to develop in response to endotoxin exposure [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. It is also interesting to note that endotoxin exposure elicits a quantitatively superior (Carter, S., et al. Unpublished data) maturation response to glucocorticoids at an 8-day exposure to delivery interval. Additional studies have similarly shown that combined endotoxin and glucocorticoid exposures have an additive effect on fetal lung maturation [<xref ref-type="bibr" rid="CR49">49</xref>]. Further investigation may assist our understanding of different pathways to accelerated fetal lung maturation and allow development of a cfRNA test for lung maturation to be utilized in the setting of obstetric syndromes like chorioamnionitis. In addition to being of interest from a fundamental biology perspective, these data are of importance as evidence suggests that ANS therapy may increase the risk of neonatal sepsis in this setting [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p></sec><sec id="Sec21"><title>Clinical implications</title><p id="Par59">The findings of this study represent a significant step forward in the development of targeted, real-time liquid biopsies for fetal organ development, providing a new minimally invasive window into <italic>in utero</italic> life. This test has the potential to significantly aid the careful selection of patients for ANS in women at risk of preterm birth, thereby maximizing benefit while minimizing potential harms from this important treatment. Additionally, this test may provide critical information about fetal maturation status to help guide delivery planning, especially in situations such as pre-eclampsia or severe intrauterine growth restriction, where the clinician must weigh up the risk of iatrogenic preterm birth vs the risk of not delivering and worsening disease. Furthermore, this test may provide valuable information for the neonatal team prior to a preterm delivery in order to prepare for postnatal care and need for neonatal intensive care or invasive ventilation.</p><p id="Par60">Our targeted approach to cfRNA analysis has several advantages in addition to the minimally invasive nature of the test (compared to legacy tests requiring invasive amniocentesis). Firstly, targeted cfRNA analysis is rapid, providing results within hours of sample collection and is relatively inexpensive due to the utilization of quantitative PCR analysis. With further development, it is expected that both the cost and time to a result may be significantly lessened allowing for the application as a clinical bedside test. This is a distinct difference from other studies utilizing cfRNA for the prediction for PTB or pre-eclampsia that have employed bulk sequencing techniques which are slower, comparatively costly, and require specialized bioinformatic analysis of large volumes of data [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par61">Although this test was designed specifically with the optimisation of patient selection for ANS in mind, the technology has wide ranging potential to be utilized for predicting development and maturation of other fetal organs and systems as well as detecting abnormalities or <italic>in utero</italic> insults such as antenatal ischemic encephalopathy or chorioamnionitis. Additionally, further development of this approach has the potential to be applied to the prediction of disease and disorders throughout the lifespan including in children and adults.</p></sec><sec id="Sec22"><title>Research implications</title><p id="Par62">The molecular basis of fetal lung maturation, both physiological and pharmacologically induced (i.e. in response to ANS) remains incompletely understood. Interestingly, we observed distinctly different cfRNA signatures of fetal lung maturation between maternal and fetal plasma samples. For example, in the dexamethasone-treated group, the maternal plasma cfRNA targets <italic>SFTPC</italic>, <italic>CTSH</italic>, <italic>AQP5</italic>, <italic>SFTPA1</italic>, and <italic>HOXA5</italic> contributed the most importance to the tests predictive power, while <italic>NKX2-1</italic>, <italic>HOXA2</italic>, <italic>SFTPD</italic>, <italic>VEGFA</italic>, and <italic>PTGS2</italic> contributed more significantly to the fetal plasma cfRNA test&#x02019;s predictive power (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>). Interestingly, although there was some functional overlap, there was no target commonality between the top five or bottom five targets in either the fetal or maternal plasma. Similarly, in the betamethasone group, there was only one target <italic>PTGS2</italic> in common within the top five cfRNA targets of importance in maternal and fetal plasma (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par63">Of further interest are the observed differences in RNA expression between the fetal lung tissue, and cfRNA expression in the maternal and fetal plasma from animals with steroid-induced lung maturation. In our dataset, the cfRNA signature in maternal plasma which predicted lung maturation, correlated closely with fetal lung tissue RNA expression in lambs with mature lungs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A). Specifically, three of the top five maternal plasma cfRNA gene targets <italic>SFTPC</italic>, <italic>CTSH</italic>, and <italic>SFTPA1</italic> were significantly upregulated in lung tissue RNA from lambs with mature lungs compared to lambs with immature lungs (saline control group animals). Interestingly, there was little commonality between the fetal plasma cfRNA signature and fetal lung tissue RNA expression in this group. Specifically, we observed no significant upregulation in fetal lung tissue RNA expression of any of the top five most important fetal plasma cfRNA gene targets being <italic>NKX2-1</italic>, <italic>HOXA2</italic>, <italic>SFTPD</italic>, <italic>VEGFA</italic>, or <italic>PTGS2</italic> (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). Furthermore, the genes <italic>ABCA3</italic>, <italic>SFTPB</italic>, <italic>SFTPC</italic>, and <italic>SFTPA1</italic> which are known to be strongly associated with fetal lung maturation and surfactant production were observed to be the cfRNA targets with the least amount of importance in fetal plasma for predicting lung maturation (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). It is possible that the immature vascular network in the preterm fetal lung results in poor plasma cfRNA uptake and that the cfRNA signal is more readily introduced into the amniotic fluid (noting that the late preterm fetal sheep lung exudes&#x02009;~&#x02009;5&#x000a0;ml/kg/h of fluid into the amniotic cavity) than the fetal plasma [<xref ref-type="bibr" rid="CR52">52</xref>]. Alternatively, it is also possible that the maternal cfRNA plasma signal was largely, if not exclusively, maternal in origin, with the maternal lung the most likely source organ. This hypothesis may suggest that, at least in the sheep, observed maternal plasma cfRNA responses to glucocorticoid stimulation are strongly predictive of fetal lung responses and may confer a heritable influence on steroid responsiveness. Finally, we may speculate that fetal cfRNA related to lung maturation more readily crosses or is actively transported across the placenta into maternal circulation. With different ANS regimens (dexamethasone vs. betamethasone) inducing different functional effects on the placenta, leading to differences in cfRNA expression in maternal plasma.</p><p id="Par64">We also observed distinct patterns of cfRNA expression in maternal plasma between the different models of lung maturation (steroid induced and physiological) as well as between sheep and human samples. Firstly, we observed different patterns of maternal plasma cfRNA expression between dexamethasone (<italic>SFTPC</italic>, <italic>CTSH</italic>, <italic>AQP5</italic>, <italic>SFTPA1</italic>, <italic>HOXA5</italic>), betamethasone (<italic>MAPK3</italic>, <italic>VEGFA</italic>, <italic>SFTPC</italic>, <italic>ABCA3</italic>, <italic>PTGS2</italic>), and betamethasone 8-day (<italic>SFTPB</italic>, <italic>FOXA2</italic>, <italic>SFTPC</italic>, <italic>SFTPAI</italic>, <italic>HPSB1</italic>) groups. <italic>SFTPC</italic> was the only common target expressed within the top five targets of importance between all these groups. <italic>SFTPC</italic> plays a critical role in the production of surfactant which acts as a thin lipid film on the surface of the lung to reduce surface tension during inhalation and facilitates lung expansion [<xref ref-type="bibr" rid="CR53">53</xref>]. A lack of surfactant in the preterm lung contributes to the pathophysiological basis behind respiratory distress syndrome; therefore, its presence is a sign of maturation. Overall, the observed differences in the cfRNA signatures between steroid exposed groups may reflect different pharmaco-molecular processes of fetal lung maturation between these two widely administered antenatal steroids and with different duration of exposure. Secondly, in sheep samples, we observed distinct differences in cfRNA expression between steroid-induced groups and the term samples (<italic>PIK3R3</italic>, <italic>HOXA5</italic>, <italic>AKT1</italic>, <italic>FOXA2</italic>, <italic>LYZ)</italic> suggesting that ANS may exert different maturation effects on the fetal lung compared to physiological term maturation. Finally, we observed differences in term cfRNA expression between sheep and the 3rd trimester human samples (<italic>FOXA2</italic>, <italic>AQP5</italic>, <italic>MAPK3</italic>, <italic>LPCAT1</italic>, <italic>SFTPB</italic>). However, <italic>FOXA2</italic> was noted to be one of the most important targets to lung maturation prediction across human and sheep term samples, as well as in the 8d betamethasone group. Expression of <italic>FOXA2</italic> in respiratory epithelial cells has been shown to be critical to many developmental processes required for fetal lung maturation and respiration including surfactant production, host defense, and lung morphogenesis [<xref ref-type="bibr" rid="CR54">54</xref>]. We note that there were differences in the gestation at which term sheep (~&#x02009;38&#x02013;39&#x000a0;weeks human equivalent gestation) and 3rd trimester human samples (~&#x02009;33<sup>+3</sup>&#x000a0;weeks gestation) were collected and this may reflect the differences observed in the cfRNA signatures. Therefore, further validation in human samples taken at term (39&#x02013;41&#x000a0;weeks&#x02019; gestation) may provide additional important insights. Overall, these findings suggest that different reference libraries of the cfRNA targets may need to be generated across different gestations for steroid induce and physiological induced lung maturation, to allow accurate comparisons to test samples in the clinical setting. This could be generated from sampling different gestational age cohorts. Finally, although the entire panel of 21 targets proved to be accurate across all groups of fetal lung maturation, further refinement utilizing different combinations of the top 5 (of the 21 targets) for each model may improve predictive accuracy depending on the indication to perform the test. For example, when utilizing the test to decide on a repeat course of ANS, a panel of five targets specific for dexamethasone or betamethasone (depending on what ANS had already been administered) would be important.</p><sec id="Sec23"><title>Strengths and limitations</title><p id="Par65">The strengths of this work relate to the use of a highly translatable sheep model of preterm lung maturation and post-natal ventilation. This model system allows for extremely rigorous control of maternal (environment, diet, behavior), fetal (gestational age) factors along with high-level standardization of treatment and sample collection. Findings from this sheep model were then validated using a human clinical sample cohort, reinforcing the translatability of both the overall approach and the panel developed.</p><p id="Par66">It is important to note that we used a biologically informed panel for this study, meaning that potential targets of interest that could have been identified using a discovery approach (i.e., by bulk sequencing of tissue or plasma) may have been missed. The twenty-one gene targets used in this study were originally isolated from human amniotic fluid samples rather than plasma, and the transport of these gene transcripts may be differentially regulated between amniotic fluid and plasma, especially so between fetus and mother [<xref ref-type="bibr" rid="CR31">31</xref>]. Further validation of our findings in a larger cohort of human pregnancy samples (including preterm, term, and steroid exposed and non-exposed) paired to delivery outcomes is required before translation into clinical practice. A pilot study utilizing this test to guide administration of ANS or not, may also be performed in late preterm patients between 34 and 37&#x000a0;weeks gestation, where the benefits of ANS are significantly lessened and most neonatal respiratory comprise can be managed adequately by neonates despite lack of steroid exposure. It is also important to note that this work represents a proof-of-principle study. Progression of this work towards clinical application will require optimisation of the analytical platform itself (i.e., rigorous technical assessments for reproducibility and batch standardization) as well as pipeline optimisation to improve speed and reduce cost. The next step in the development of this technology will be a carefully controlled, blinded prospective study performed in multiple patient populations to control for differences in clinical practice, environment, and ethnicity.</p><p id="Par67">Lastly, it should be emphasized that, as noted above, we did not seek to identify the source of the cfRNA signal used in our assays. Earlier studies have shown that the fetal-specific fraction of cfRNA in the maternal plasma is&#x02009;&#x0003c;&#x02009;1% at the end of the first trimester, but increases to reach around 15% after 24&#x000a0;weeks&#x02019; gestation [<xref ref-type="bibr" rid="CR55">55</xref>]. Thus, while noting that the majority of cfRNA in maternal plasma is not of fetal of origin, it is still reasonable to assume that (i) a material amount of fetal-origin cfRNA was present in the sheep samples and the second and third trimester human samples reported in this study and that (ii) changes in this fetal fraction may represent anatomical and functional changes in the fetal lung in response to endotoxin and glucocorticoid exposure. Although this is not an issue from a purely screening perspective (i.e., if a particular set of biological markers offer robust sensitivity and specificity for determining fetal lung maturation their origin is of secondary importance), unpacking this question is of great importance from a biological perspective. Moreover, such data may assist in the selection and testing of additional and/or more effective biological markers for assessing fetal development and disease. Further studies being undertaken by our group are designed to address this query.</p></sec></sec></sec><sec id="Sec24"><title>Conclusions</title><p id="Par68">This proof-of-principle work demonstrates that analysis of maternal plasma cfRNA serves as a novel, minimally invasive, predictive test for fetal lung maturation for both antenatal steroid induced and physiological lung maturation. The establishment of a validated, prospectively analyzed test algorithm in larger human populations has sizable potential clinical application in optimizing patient selection for both initial and repeat courses of antenatal steroids to promote preterm fetal lung maturation, particularly in the late preterm period wherein treatment benefit in a large number of mothers and fetuses is very modest relative to the risk of harms.</p></sec><sec id="Sec25" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4256_MOESM1_ESM.docx"><caption><p>Supplementary Material 1.&#x000a0;Additional Table 1. Gene target primers in Sheep. Additional Table 2. Gene target primers in Humans. Additional Table 3. Sheep and Human housekeeping gene targets <italic>ACTB</italic>, <italic>RPS18</italic>, <italic>GAPDH</italic> and internal assay control <italic>Luciferase</italic>.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ANS</term><def><p id="Par7">Antenatal corticosteroids</p></def></def-item><def-item><term>AUC</term><def><p id="Par8">Area under the receiver operating characteristic curve</p></def></def-item><def-item><term>cfRNA</term><def><p id="Par9">Cell-free RNA</p></def></def-item><def-item><term>Ct</term><def><p id="Par10">Cycle threshold</p></def></def-item><def-item><term>d GA</term><def><p id="Par11">Days gestational age</p></def></def-item><def-item><term>IM</term><def><p id="Par12">Intramuscular</p></def></def-item><def-item><term>LPS</term><def><p id="Par13">Lipopolysaccharides</p></def></def-item><def-item><term>PCR</term><def><p id="Par14">Polymerase chain reaction</p></def></def-item><def-item><term>PTB</term><def><p id="Par15">Preterm birth</p></def></def-item><def-item><term>RNA</term><def><p id="Par16">Ribonucleic acid</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>Study design and conceptualisation: SC, WK, MK. Animal studies SC, HU, EF, YK, MS,HW, TT, MK. Human studies SC, LM, RP, SI, KS, GN. Laboratory studies SC, KS, YK, WK, SE, MK. Data analysis WK, SC,KS, MK, SE. Manuscript preparation SC. Manuscript review SC, MK, WK, SI, MC. All authors read and approved the final manuscript SC, KS, SE,WK, HU,EF,YK,TT,LM,RP, GN,HW,MS,MC,SI,MK.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by a grant from the Ministry of Education, Government of Singapore (NUHSRO/2021/109/T1/Seed-Sep/02), the Stan Perron Charitable Foundation, the Women and Infants Research Foundation (Australia), and by the RANZCOG Women&#x02019;s Health Foundation Fotheringham Research Fellowship.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data corresponding to figures and tables generated as well maternal standardized Ct values for each individual cfRNA target are available in supporting data deposited at figshare. Dataset https://doi.org/10.6084/m9.figshare.27959226.v1. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request: Dr Sean William David Carter (e0983855@u.nus.edu).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par69">All animal studies were reviewed and approved by the University of Western Australia&#x02019;s Animal Ethics Committee prior to work commencing (2021/ET000974) / 2022/ET000920) and adhered to the NIH Guide for the Care and Use of Laboratory Animals and the ARRIVE guidelines on the use of laboratory animals.</p><p id="Par70">Human plasma samples were collected at the Gynecology and Obstetrics Department of Hospital Parroquial de San Bernardo, Santiago, Chile. All women enrolled in this study gave written informed consent for the collection of samples and information. This research was approved by the Ethical Scientific Committees of Universidad de los Andes, Chile.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par71">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par72">SWDC, WK, SEP and MWK are listed as inventors for PCT Patent Application No.PCT/SG2024/050608.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Blencowe</surname><given-names>H</given-names></name><name><surname>Cousens</surname><given-names>S</given-names></name><name><surname>Chou</surname><given-names>D</given-names></name><name><surname>Oestergaard</surname><given-names>M</given-names></name><name><surname>Say</surname><given-names>L</given-names></name><name><surname>Moller</surname><given-names>AB</given-names></name><name><surname>Kinney</surname><given-names>M</given-names></name><name><surname>Lawn</surname><given-names>J</given-names></name></person-group><article-title>Born too soon: the global epidemiology of 15 million preterm births</article-title><source>Reprod Health</source><year>2013</year><volume>10 Suppl 1</volume><issue>Suppl 1</issue><fpage>S2</fpage><pub-id pub-id-type="pmid">24625129</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Blencowe H, Cousens S, Chou D, Oestergaard M, Say L, Moller AB, Kinney M, Lawn J. Born too soon: the global epidemiology of 15 million preterm births. Reprod Health. 2013;10 Suppl 1(Suppl 1):S2.<pub-id pub-id-type="pmid">24625129</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>RL</given-names></name><name><surname>Culhane</surname><given-names>JF</given-names></name><name><surname>Iams</surname><given-names>JD</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name></person-group><article-title>Epidemiology and causes of preterm birth</article-title><source>Lancet</source><year>2008</year><volume>371</volume><issue>9606</issue><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">18177778</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75&#x02013;84.<pub-id pub-id-type="pmid">18177778</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Lawn</surname><given-names>JE</given-names></name><name><surname>Gravett</surname><given-names>MG</given-names></name><name><surname>Nunes</surname><given-names>TM</given-names></name><name><surname>Rubens</surname><given-names>CE</given-names></name><name><surname>Stanton</surname><given-names>C</given-names></name></person-group><article-title>the GRG: Global report on preterm birth and stillbirth (1 of 7): definitions, description of the burden and opportunities to improve data</article-title><source>BMC Pregnancy Childbirth</source><year>2010</year><volume>10</volume><issue>1</issue><fpage>S1</fpage><pub-id pub-id-type="pmid">20233382</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Lawn JE, Gravett MG, Nunes TM, Rubens CE, Stanton C. the GRG: Global report on preterm birth and stillbirth (1 of 7): definitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth. 2010;10(1):S1.<pub-id pub-id-type="pmid">20233382</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Liggins</surname><given-names>GC</given-names></name><name><surname>Howie</surname><given-names>RN</given-names></name></person-group><article-title>A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants</article-title><source>Pediatrics</source><year>1972</year><volume>50</volume><issue>4</issue><fpage>515</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">4561295</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515&#x02013;25.<pub-id pub-id-type="pmid">4561295</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Carter</surname><given-names>SW</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Clarke</surname><given-names>MW</given-names></name><name><surname>Ireland</surname><given-names>DJ</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name></person-group><article-title>Single-nucleotide polymorphisms in dizygotic twin ovine fetuses are associated with discordant responses to antenatal steroid therapy</article-title><source>BMC Med</source><year>2025</year><volume>23</volume><issue>1</issue><fpage>65</fpage><pub-id pub-id-type="pmid">39901164</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Fee EL, Usuda H, Carter SW, Ikeda H, Takahashi T, Takahashi Y, Kumagai Y, Clarke MW, Ireland DJ, Newnham JP. Single-nucleotide polymorphisms in dizygotic twin ovine fetuses are associated with discordant responses to antenatal steroid therapy. BMC Med. 2025;23(1):65.<pub-id pub-id-type="pmid">39901164</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Porto</surname><given-names>AMF</given-names></name><name><surname>Coutinho</surname><given-names>IC</given-names></name><name><surname>Correia</surname><given-names>JB</given-names></name><name><surname>Amorim</surname><given-names>MMR</given-names></name></person-group><article-title>Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial</article-title><source>BMJ</source><year>2011</year><volume>342</volume><fpage>d1696</fpage><pub-id pub-id-type="pmid">21487057</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Porto AMF, Coutinho IC, Correia JB, Amorim MMR. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ. 2011;342:d1696.<pub-id pub-id-type="pmid">21487057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>McKinlay</surname><given-names>CJD</given-names></name><name><surname>Alsweiler</surname><given-names>JM</given-names></name><name><surname>Anstice</surname><given-names>NS</given-names></name><name><surname>Burakevych</surname><given-names>N</given-names></name><name><surname>Chakraborty</surname><given-names>A</given-names></name><name><surname>Chase</surname><given-names>JG</given-names></name><name><surname>Gamble</surname><given-names>GD</given-names></name><name><surname>Harris</surname><given-names>DL</given-names></name><name><surname>Jacobs</surname><given-names>RJ</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years</article-title><source>JAMA Pediatr</source><year>2017</year><volume>171</volume><issue>10</issue><fpage>972</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">28783802</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">McKinlay CJD, Alsweiler JM, Anstice NS, Burakevych N, Chakraborty A, Chase JG, Gamble GD, Harris DL, Jacobs RJ, Jiang Y, et al. Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years. JAMA Pediatr. 2017;171(10):972&#x02013;83.<pub-id pub-id-type="pmid">28783802</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Souter</surname><given-names>V</given-names></name><name><surname>Kauffman</surname><given-names>E</given-names></name><name><surname>Marshall</surname><given-names>AJ</given-names></name><name><surname>Katon</surname><given-names>JG</given-names></name></person-group><article-title>Assessing the potential impact of extending antenatal steroids to the late preterm period</article-title><source>Am J Obstet Gynecol</source><year>2017</year><volume>217</volume><issue>4</issue><fpage>461.e461</fpage><lpage>461.e467</lpage></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Souter V, Kauffman E, Marshall AJ, Katon JG. Assessing the potential impact of extending antenatal steroids to the late preterm period. Am J Obstet Gynecol. 2017;217(4):461.e461-461.e467.</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>J</given-names></name><name><surname>Shennan</surname><given-names>A</given-names></name><name><surname>Jacobsson</surname><given-names>B</given-names></name><name><surname>Stock</surname><given-names>SJ</given-names></name></person-group><article-title>Birth FWGfP: FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm</article-title><source>Int J Gynaecol Obstet</source><year>2021</year><volume>155</volume><issue>1</issue><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">34520057</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Norman J, Shennan A, Jacobsson B, Stock SJ. Birth FWGfP: FIGO good practice recommendations on the use of prenatal corticosteroids to improve outcomes and minimize harm in babies born preterm. Int J Gynaecol Obstet. 2021;155(1):26&#x02013;30.<pub-id pub-id-type="pmid">34520057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>McGoldrick</surname><given-names>E</given-names></name><name><surname>Stewart</surname><given-names>F</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name><name><surname>Dalziel</surname><given-names>SR</given-names></name></person-group><article-title>Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth</article-title><source>Cochrane Database Syst Rev</source><year>2020</year><volume>12</volume><fpage>CD004454</fpage><pub-id pub-id-type="pmid">33368142</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2020;12:CD004454.<pub-id pub-id-type="pmid">33368142</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Clapp</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>JL</given-names></name><name><surname>Gyamfi-Bannerman</surname><given-names>C</given-names></name><name><surname>Knudsen</surname><given-names>AB</given-names></name><name><surname>Lorch</surname><given-names>SA</given-names></name><name><surname>Thaweethai</surname><given-names>T</given-names></name><name><surname>Wright</surname><given-names>JD</given-names></name><name><surname>Kaimal</surname><given-names>AJ</given-names></name><name><surname>Melamed</surname><given-names>A</given-names></name></person-group><article-title>Betamethasone exposure and neonatal respiratory morbidity among late preterm births by planned mode of delivery and gestational age</article-title><source>Obstet Gynecol</source><year>2024</year><volume>144</volume><issue>6</issue><fpage>747</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">39388700</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Clapp MA, Li S, Cohen JL, Gyamfi-Bannerman C, Knudsen AB, Lorch SA, Thaweethai T, Wright JD, Kaimal AJ, Melamed A. Betamethasone exposure and neonatal respiratory morbidity among late preterm births by planned mode of delivery and gestational age. Obstet Gynecol. 2024;144(6):747&#x02013;54.<pub-id pub-id-type="pmid">39388700</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Makhija</surname><given-names>NK</given-names></name><name><surname>Tronnes</surname><given-names>AA</given-names></name><name><surname>Dunlap</surname><given-names>BS</given-names></name><name><surname>Schulkin</surname><given-names>J</given-names></name><name><surname>Lannon</surname><given-names>SM</given-names></name></person-group><article-title>Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol</article-title><source>Am J Obstet Gynecol</source><year>2016</year><volume>214</volume><issue>1</issue><fpage>120. e121</fpage><lpage>120. e126</lpage></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Makhija NK, Tronnes AA, Dunlap BS, Schulkin J, Lannon SM. Antenatal corticosteroid timing: accuracy after the introduction of a rescue course protocol. Am J Obstet Gynecol. 2016;214(1):120. e121-120. e126.</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ali Khan</surname><given-names>A</given-names></name><name><surname>Cartwright</surname><given-names>R</given-names></name><name><surname>Gissler</surname><given-names>M</given-names></name><name><surname>J&#x000e4;rvelin</surname><given-names>M-R</given-names></name></person-group><article-title>Antenatal corticosteroid therapy (ACT) and size at birth: a population-based analysis using the finnish medical birth register</article-title><source>PLoS Med</source><year>2019</year><volume>16</volume><issue>2</issue><fpage>e1002746</fpage><pub-id pub-id-type="pmid">30807570</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Rodriguez A, Wang Y, Ali Khan A, Cartwright R, Gissler M, J&#x000e4;rvelin M-R. Antenatal corticosteroid therapy (ACT) and size at birth: a population-based analysis using the finnish medical birth register. PLoS Med. 2019;16(2):e1002746.<pub-id pub-id-type="pmid">30807570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Middleton</surname><given-names>PF</given-names></name><name><surname>Voysey</surname><given-names>M</given-names></name><name><surname>Askie</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Martlow</surname><given-names>TK</given-names></name><name><surname>Aghajafari</surname><given-names>F</given-names></name><name><surname>Asztalos</surname><given-names>EV</given-names></name><name><surname>Brocklehurst</surname><given-names>P</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name></person-group><article-title>Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis</article-title><source>PLoS Med</source><year>2019</year><volume>16</volume><issue>4</issue><fpage>e1002771</fpage><pub-id pub-id-type="pmid">30978205</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Crowther CA, Middleton PF, Voysey M, Askie L, Zhang S, Martlow TK, Aghajafari F, Asztalos EV, Brocklehurst P, Dutta S. Effects of repeat prenatal corticosteroids given to women at risk of preterm birth: An individual participant data meta-analysis. PLoS Med. 2019;16(4):e1002771.<pub-id pub-id-type="pmid">30978205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>E</given-names></name><name><surname>Waffarn</surname><given-names>F</given-names></name><name><surname>Uy</surname><given-names>C</given-names></name><name><surname>Hobel</surname><given-names>C</given-names></name><name><surname>Glynn</surname><given-names>L</given-names></name><name><surname>Sandman</surname><given-names>C</given-names></name></person-group><article-title>Effect of prenatal glucocorticoid treatment on size at birth among infants born at term gestation</article-title><source>J Perinatol</source><year>2009</year><volume>29</volume><issue>11</issue><fpage>731</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">19587690</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Davis E, Waffarn F, Uy C, Hobel C, Glynn L, Sandman C. Effect of prenatal glucocorticoid treatment on size at birth among infants born at term gestation. J Perinatol. 2009;29(11):731&#x02013;7.<pub-id pub-id-type="pmid">19587690</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>KE</given-names></name><name><surname>Hannah</surname><given-names>ME</given-names></name><name><surname>Willan</surname><given-names>AR</given-names></name><name><surname>Hewson</surname><given-names>SA</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>EN</given-names></name><name><surname>Matthews</surname><given-names>SG</given-names></name><name><surname>Saigal</surname><given-names>S</given-names></name><name><surname>Asztalos</surname><given-names>E</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name></person-group><article-title>Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial</article-title><source>The Lancet</source><year>2008</year><volume>372</volume><issue>9656</issue><fpage>2143</fpage><lpage>2151</lpage></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Murphy KE, Hannah ME, Willan AR, Hewson SA, Ohlsson A, Kelly EN, Matthews SG, Saigal S, Asztalos E, Ross S. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. The Lancet. 2008;372(9656):2143&#x02013;51.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Asztalos</surname><given-names>E</given-names></name><name><surname>Willan</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Matthews</surname><given-names>S</given-names></name><name><surname>Ohlsson</surname><given-names>A</given-names></name><name><surname>Saigal</surname><given-names>S</given-names></name><name><surname>Armson</surname><given-names>A</given-names></name><name><surname>Kelly</surname><given-names>E</given-names></name><name><surname>Delisle</surname><given-names>M-F</given-names></name><name><surname>Gafni</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5)</article-title><source>BMC Pregnancy Childbirth</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>272</fpage><pub-id pub-id-type="pmid">25123162</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Asztalos E, Willan A, Murphy K, Matthews S, Ohlsson A, Saigal S, Armson A, Kelly E, Delisle M-F, Gafni A, et al. Association between gestational age at birth, antenatal corticosteroids, and outcomes at 5 years: multiple courses of antenatal corticosteroids for preterm birth study at 5 years of age (MACS-5). BMC Pregnancy Childbirth. 2014;14(1):272.<pub-id pub-id-type="pmid">25123162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname><given-names>JR</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Gibson</surname><given-names>N</given-names></name><name><surname>Holland</surname><given-names>G</given-names></name><name><surname>Lin</surname><given-names>TM</given-names></name><name><surname>Swearingen</surname><given-names>CJ</given-names></name><name><surname>Mehl</surname><given-names>JK</given-names></name><name><surname>ElHassan</surname><given-names>NO</given-names></name></person-group><article-title>Association between transient newborn hypoglycemia and fourth-grade achievement test proficiency: a population-based study</article-title><source>JAMA Pediatr</source><year>2015</year><volume>169</volume><issue>10</issue><fpage>913</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">26301959</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kaiser JR, Bai S, Gibson N, Holland G, Lin TM, Swearingen CJ, Mehl JK, ElHassan NO. Association between transient newborn hypoglycemia and fourth-grade achievement test proficiency: a population-based study. JAMA Pediatr. 2015;169(10):913&#x02013;21.<pub-id pub-id-type="pmid">26301959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Dalziel</surname><given-names>SR</given-names></name><name><surname>Walker</surname><given-names>NK</given-names></name><name><surname>Parag</surname><given-names>V</given-names></name><name><surname>Mantell</surname><given-names>C</given-names></name><name><surname>Rea</surname><given-names>HH</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Harding</surname><given-names>JE</given-names></name></person-group><article-title>Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial</article-title><source>The Lancet</source><year>2005</year><volume>365</volume><issue>9474</issue><fpage>1856</fpage><lpage>1862</lpage></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Dalziel SR, Walker NK, Parag V, Mantell C, Rea HH, Rodgers A, Harding JE. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. The Lancet. 2005;365(9474):1856&#x02013;62.</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000e4;ikk&#x000f6;nen</surname><given-names>K</given-names></name><name><surname>Gissler</surname><given-names>M</given-names></name><name><surname>Kajantie</surname><given-names>E</given-names></name></person-group><article-title>Associations between maternal antenatal corticosteroid treatment and mental and behavioral disorders in children</article-title><source>JAMA</source><year>2020</year><volume>323</volume><issue>19</issue><fpage>1924</fpage><lpage>1933</lpage><pub-id pub-id-type="pmid">32427304</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">R&#x000e4;ikk&#x000f6;nen K, Gissler M, Kajantie E. Associations between maternal antenatal corticosteroid treatment and mental and behavioral disorders in children. JAMA. 2020;323(19):1924&#x02013;33.<pub-id pub-id-type="pmid">32427304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Stutchfield</surname><given-names>PR</given-names></name><name><surname>Whitaker</surname><given-names>R</given-names></name><name><surname>Gliddon</surname><given-names>AE</given-names></name><name><surname>Hobson</surname><given-names>L</given-names></name><name><surname>Kotecha</surname><given-names>S</given-names></name><name><surname>Doull</surname><given-names>IJ</given-names></name></person-group><article-title>Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial)</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2013</year><volume>98</volume><issue>3</issue><fpage>F195</fpage><lpage>F200</lpage><pub-id pub-id-type="pmid">23424017</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Stutchfield PR, Whitaker R, Gliddon AE, Hobson L, Kotecha S, Doull IJ. Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Arch Dis Child Fetal Neonatal Ed. 2013;98(3):F195&#x02013;200.<pub-id pub-id-type="pmid">23424017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>AG</given-names></name><name><surname>Gamble</surname><given-names>GD</given-names></name><name><surname>Crowther</surname><given-names>CA</given-names></name><name><surname>Dalziel</surname><given-names>SR</given-names></name><name><surname>Eagleton</surname><given-names>CL</given-names></name><name><surname>McKinlay</surname><given-names>CJ</given-names></name><name><surname>Milne</surname><given-names>BJ</given-names></name><name><surname>Harding</surname><given-names>JE</given-names></name></person-group><article-title>Cardiovascular outcomes 50 years after antenatal exposure to betamethasone: Follow-up of a randomised double-blind, placebo-controlled trial</article-title><source>PLoS Med</source><year>2024</year><volume>21</volume><issue>4</issue><fpage>e1004378</fpage><pub-id pub-id-type="pmid">38557442</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Walters AG, Gamble GD, Crowther CA, Dalziel SR, Eagleton CL, McKinlay CJ, Milne BJ, Harding JE. Cardiovascular outcomes 50 years after antenatal exposure to betamethasone: Follow-up of a randomised double-blind, placebo-controlled trial. PLoS Med. 2024;21(4):e1004378.<pub-id pub-id-type="pmid">38557442</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Dalziel</surname><given-names>SR</given-names></name><name><surname>Lim</surname><given-names>VK</given-names></name><name><surname>Lambert</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>D</given-names></name><name><surname>Parag</surname><given-names>V</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Harding</surname><given-names>JE</given-names></name></person-group><article-title>Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial</article-title><source>BMJ</source><year>2005</year><volume>331</volume><issue>7518</issue><fpage>665</fpage><pub-id pub-id-type="pmid">16143712</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Dalziel SR, Lim VK, Lambert A, McCarthy D, Parag V, Rodgers A, Harding JE. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ. 2005;331(7518):665.<pub-id pub-id-type="pmid">16143712</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Karcher</surname><given-names>R</given-names></name><name><surname>Sykes</surname><given-names>E</given-names></name><name><surname>Batton</surname><given-names>D</given-names></name><name><surname>Uddin</surname><given-names>Z</given-names></name><name><surname>Ross</surname><given-names>G</given-names></name><name><surname>Hockman</surname><given-names>E</given-names></name><name><surname>Shade</surname><given-names>GH</given-names></name></person-group><article-title>Gestational age-specific predicted risk of neonatal respiratory distress syndrome using lamellar body count and surfactant-to-albumin ratio in amniotic fluid</article-title><source>Am J Obstet Gynecol</source><year>2005</year><volume>193</volume><issue>5</issue><fpage>1680</fpage><lpage>1684</lpage><pub-id pub-id-type="pmid">16260210</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Karcher R, Sykes E, Batton D, Uddin Z, Ross G, Hockman E, Shade GH. Gestational age-specific predicted risk of neonatal respiratory distress syndrome using lamellar body count and surfactant-to-albumin ratio in amniotic fluid. Am J Obstet Gynecol. 2005;193(5):1680&#x02013;4.<pub-id pub-id-type="pmid">16260210</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Besnard</surname><given-names>AE</given-names></name><name><surname>Wirjosoekarto</surname><given-names>SAM</given-names></name><name><surname>Broeze</surname><given-names>KA</given-names></name><name><surname>Opmeer</surname><given-names>BC</given-names></name><name><surname>Mol</surname><given-names>BWJ</given-names></name></person-group><article-title>Lecithin/sphingomyelin ratio and lamellar body count for fetal lung maturity: a meta-analysis</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2013</year><volume>169</volume><issue>2</issue><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">23481577</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Besnard AE, Wirjosoekarto SAM, Broeze KA, Opmeer BC, Mol BWJ. Lecithin/sphingomyelin ratio and lamellar body count for fetal lung maturity: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):177&#x02013;83.<pub-id pub-id-type="pmid">23481577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Tabor</surname><given-names>A</given-names></name><name><surname>Madsen</surname><given-names>M</given-names></name><name><surname>Obel</surname><given-names>E</given-names></name><name><surname>Philip</surname><given-names>J</given-names></name><name><surname>Bang</surname><given-names>J</given-names></name><name><surname>Gaard-Pedersen</surname><given-names>B</given-names></name></person-group><article-title>Randomised controlled trial of genetic amniocentesis in 4606 low-risk women</article-title><source>The Lancet</source><year>1986</year><volume>327</volume><issue>8493</issue><fpage>1287</fpage><lpage>1293</lpage></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Tabor A, Madsen M, Obel E, Philip J, Bang J, Gaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. The Lancet. 1986;327(8493):1287&#x02013;93.</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Cederholm</surname><given-names>M</given-names></name><name><surname>Haglund</surname><given-names>B</given-names></name><name><surname>Axelsson</surname><given-names>O</given-names></name></person-group><article-title>Infant morbidity following amniocentesis and chorionic villus sampling for prenatal karyotyping</article-title><source>BJOG</source><year>2005</year><volume>112</volume><issue>4</issue><fpage>394</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">15777434</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Cederholm M, Haglund B, Axelsson O. Infant morbidity following amniocentesis and chorionic villus sampling for prenatal karyotyping. BJOG. 2005;112(4):394&#x02013;402.<pub-id pub-id-type="pmid">15777434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Moufarrej</surname><given-names>MN</given-names></name><name><surname>Vorperian</surname><given-names>SK</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name><name><surname>Campos</surname><given-names>AA</given-names></name><name><surname>Quaintance</surname><given-names>CC</given-names></name><name><surname>Sit</surname><given-names>RV</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Detweiler</surname><given-names>AM</given-names></name><name><surname>Mekonen</surname><given-names>H</given-names></name><name><surname>Neff</surname><given-names>NF</given-names></name><etal/></person-group><article-title>Early prediction of preeclampsia in pregnancy with cell-free RNA</article-title><source>Nature</source><year>2022</year><volume>602</volume><issue>7898</issue><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">35140405</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Moufarrej MN, Vorperian SK, Wong RJ, Campos AA, Quaintance CC, Sit RV, Tan M, Detweiler AM, Mekonen H, Neff NF, et al. Early prediction of preeclampsia in pregnancy with cell-free RNA. Nature. 2022;602(7898):689&#x02013;94.<pub-id pub-id-type="pmid">35140405</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Ngo</surname><given-names>TTM</given-names></name><name><surname>Moufarrej</surname><given-names>MN</given-names></name><name><surname>Rasmussen</surname><given-names>MLH</given-names></name><name><surname>Camunas-Soler</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Okamoto</surname><given-names>J</given-names></name><name><surname>Neff</surname><given-names>NF</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>RJ</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><etal/></person-group><article-title>Noninvasive blood tests for fetal development predict gestational age and preterm delivery</article-title><source>Science</source><year>2018</year><volume>360</volume><issue>6393</issue><fpage>1133</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">29880692</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ngo TTM, Moufarrej MN, Rasmussen MLH, Camunas-Soler J, Pan W, Okamoto J, Neff NF, Liu K, Wong RJ, Downes K, et al. Noninvasive blood tests for fetal development predict gestational age and preterm delivery. Science. 2018;360(6393):1133&#x02013;6.<pub-id pub-id-type="pmid">29880692</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>DW</given-names></name><name><surname>Maron</surname><given-names>JL</given-names></name><name><surname>Johnson</surname><given-names>KL</given-names></name></person-group><article-title>Insights into fetal and neonatal development through analysis of cell-free RNA in body fluids</article-title><source>Early Hum Dev</source><year>2010</year><volume>86</volume><issue>11</issue><fpage>747</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">20851538</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Bianchi DW, Maron JL, Johnson KL. Insights into fetal and neonatal development through analysis of cell-free RNA in body fluids. Early Hum Dev. 2010;86(11):747&#x02013;52.<pub-id pub-id-type="pmid">20851538</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath-Rayne</surname><given-names>BD</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>EA</given-names></name><name><surname>Muglia</surname><given-names>LJ</given-names></name><name><surname>DeFranco</surname><given-names>EA</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Salomonis</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Systems biology evaluation of cell-free amniotic fluid transcriptome of term and preterm infants to detect fetal maturity</article-title><source>BMC Med Genomics</source><year>2015</year><volume>8</volume><fpage>67</fpage><pub-id pub-id-type="pmid">26493725</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Kamath-Rayne BD, Du Y, Hughes M, Wagner EA, Muglia LJ, DeFranco EA, Whitsett JA, Salomonis N, Xu Y. Systems biology evaluation of cell-free amniotic fluid transcriptome of term and preterm infants to detect fetal maturity. BMC Med Genomics. 2015;8:67.<pub-id pub-id-type="pmid">26493725</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Carter</surname><given-names>S</given-names></name><name><surname>Furfaro</surname><given-names>L</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><name><surname>Milad</surname><given-names>MA</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name></person-group><article-title>Low-dose antenatal betamethasone treatment achieves preterm lung maturation equivalent to that of the World Health Organization dexamethasone regimen but with reduced endocrine disruption in a sheep model of pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2022</year><volume>227</volume><issue>6</issue><fpage>903. e901</fpage><lpage>903. e916</lpage></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Usuda H, Fee EL, Carter S, Furfaro L, Takahashi T, Takahashi Y, Newnham JP, Milad MA, Saito M, Jobe AH. Low-dose antenatal betamethasone treatment achieves preterm lung maturation equivalent to that of the World Health Organization dexamethasone regimen but with reduced endocrine disruption in a sheep model of pregnancy. Am J Obstet Gynecol. 2022;227(6):903. e901-903. e916.</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Hanita</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Koshinami</surname><given-names>S</given-names></name></person-group><article-title>Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2020</year><volume>223</volume><issue>6</issue><fpage>921. e921</fpage><lpage>921. e910</lpage></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Takahashi T, Saito M, Schmidt AF, Usuda H, Takahashi Y, Watanabe S, Hanita T, Sato S, Kumagai Y, Koshinami S. Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy. Am J Obstet Gynecol. 2020;223(6):921. e921-921. e910.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Yaegashi</surname><given-names>N</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Furfaro</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name></person-group><article-title>Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate</article-title><source>Am J Obstet Gynecol</source><year>2022</year><volume>226</volume><issue>4</issue><fpage>564. e561</fpage><lpage>564. e514</lpage></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Takahashi T, Fee EL, Takahashi Y, Saito M, Yaegashi N, Usuda H, Furfaro L, Carter S, Schmidt AF, Newnham JP. Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate. Am J Obstet Gynecol. 2022;226(4):564. e561-564. e514.</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>SW</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Oguz</surname><given-names>G</given-names></name><name><surname>Ramasamy</surname><given-names>A</given-names></name><name><surname>Amin</surname><given-names>Z</given-names></name><name><surname>Agnihotri</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Xiawen</surname><given-names>L</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name></person-group><article-title>Antenatal steroids elicited neurodegenerative-associated transcriptional changes in the hippocampus of preterm fetal sheep independent of lung maturation</article-title><source>BMC Med</source><year>2024</year><volume>22</volume><issue>1</issue><fpage>338</fpage><pub-id pub-id-type="pmid">39183288</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Carter SW, Fee EL, Usuda H, Oguz G, Ramasamy A, Amin Z, Agnihotri B, Wei Q, Xiawen L, Takahashi T. Antenatal steroids elicited neurodegenerative-associated transcriptional changes in the hippocampus of preterm fetal sheep independent of lung maturation. BMC Med. 2024;22(1):338.<pub-id pub-id-type="pmid">39183288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Carter</surname><given-names>SW</given-names></name><name><surname>Clarke</surname><given-names>MW</given-names></name><name><surname>Milad</surname><given-names>MA</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name></person-group><article-title>Respiratory benefit in preterm lambs is progressively lost when the concentration of fetal plasma betamethasone is titrated below two nanograms per milliliter</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2023</year><volume>325</volume><issue>5</issue><fpage>L628</fpage><lpage>L637</lpage><pub-id pub-id-type="pmid">37697929</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Fee EL, Takahashi T, Takahashi Y, Carter SW, Clarke MW, Milad MA, Usuda H, Ikeda H, Kumagai Y, Saito Y. Respiratory benefit in preterm lambs is progressively lost when the concentration of fetal plasma betamethasone is titrated below two nanograms per milliliter. Am J Physiol Lung Cell Mol Physiol. 2023;325(5):L628&#x02013;37.<pub-id pub-id-type="pmid">37697929</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Liaw</surname><given-names>A</given-names></name><name><surname>Wiener</surname><given-names>M</given-names></name></person-group><article-title>Classification and regression by randomForest</article-title><source>R news</source><year>2002</year><volume>2</volume><issue>3</issue><fpage>18</fpage><lpage>22</lpage></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Liaw A, Wiener M. Classification and regression by randomForest. R news. 2002;2(3):18&#x02013;22.</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><name><surname>Averick</surname><given-names>M</given-names></name><name><surname>Bryan</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>McGowan</surname><given-names>LDA</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>R</given-names></name><name><surname>Grolemund</surname><given-names>G</given-names></name><name><surname>Hayes</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>L</given-names></name><name><surname>Hester</surname><given-names>J</given-names></name></person-group><article-title>Welcome to the Tidyverse</article-title><source>J Open Source Software</source><year>2019</year><volume>4</volume><issue>43</issue><fpage>1686</fpage></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Wickham H, Averick M, Bryan J, Chang W, McGowan LDA, Fran&#x000e7;ois R, Grolemund G, Hayes A, Henry L, Hester J. Welcome to the Tidyverse. J Open Source Software. 2019;4(43):1686.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>X</given-names></name><name><surname>Turck</surname><given-names>N</given-names></name><name><surname>Hainard</surname><given-names>A</given-names></name><name><surname>Tiberti</surname><given-names>N</given-names></name><name><surname>Lisacek</surname><given-names>F</given-names></name><name><surname>Sanchez</surname><given-names>J-C</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>M</given-names></name></person-group><article-title>pROC: an open-source package for R and S+ to analyze and compare ROC curves</article-title><source>BMC Bioinformatics</source><year>2011</year><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">21199577</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, M&#x000fc;ller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12(1):1&#x02013;8.<pub-id pub-id-type="pmid">21199577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Hanita</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Koshinami</surname><given-names>S</given-names></name><etal/></person-group><article-title>Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2020</year><volume>223</volume><issue>6</issue><fpage>921.e921</fpage><lpage>921.e910</lpage></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Takahashi T, Saito M, Schmidt AF, Usuda H, Takahashi Y, Watanabe S, Hanita T, Sato S, Kumagai Y, Koshinami S, et al. Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy. Am J Obstet Gynecol. 2020;223(6):921.e921-921.e910.</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Yaegashi</surname><given-names>N</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Furfaro</surname><given-names>L</given-names></name><name><surname>Carter</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birth weights when administered to pregnant sheep in combination with betamethasone acetate</article-title><source>Am J Obstet Gynecol</source><year>2021</year><volume>226</volume><issue>4</issue><fpage>564</fpage><lpage>e1</lpage></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Takahashi T, Fee EL, Takahashi Y, Saito M, Yaegashi N, Usuda H, Furfaro L, Carter S, Schmidt AF, Newnham JP, et al. Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birth weights when administered to pregnant sheep in combination with betamethasone acetate. Am J Obstet Gynecol. 2021;226(4):564-e1.</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Hanita</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Kumagai</surname><given-names>Y</given-names></name><name><surname>Koshinami</surname><given-names>S</given-names></name><etal/></person-group><article-title>Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy</article-title><source>Am J Obstet Gynecol</source><year>2020</year><volume>223</volume><issue>6</issue><fpage>921 e921</fpage><lpage>921 e910</lpage></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Takahashi T, Saito M, Schmidt AF, Usuda H, Takahashi Y, Watanabe S, Hanita T, Sato S, Kumagai Y, Koshinami S, et al. Variability in the efficacy of a standardized antenatal steroid treatment was independent of maternal or fetal plasma drug levels: evidence from a sheep model of pregnancy. Am J Obstet Gynecol. 2020;223(6):921 e921-921 e910.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Milad</surname><given-names>MA</given-names></name><name><surname>Peppard</surname><given-names>T</given-names></name><name><surname>Jusko</surname><given-names>WJ</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of intramuscular and oral betamethasone and dexamethasone in reproductive age women in India</article-title><source>Clin Transl Sci</source><year>2020</year><volume>13</volume><issue>2</issue><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">31808984</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Jobe AH, Milad MA, Peppard T, Jusko WJ. Pharmacokinetics and pharmacodynamics of intramuscular and oral betamethasone and dexamethasone in reproductive age women in India. Clin Transl Sci. 2020;13(2):391&#x02013;9.<pub-id pub-id-type="pmid">31808984</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Lahra</surname><given-names>MM</given-names></name><name><surname>Beeby</surname><given-names>PJ</given-names></name><name><surname>Jeffery</surname><given-names>HE</given-names></name></person-group><article-title>Maternal versus fetal inflammation and respiratory distress syndrome: a 10-year hospital cohort study</article-title><source>Arch Dis Child Fetal Neonatal Ed</source><year>2009</year><volume>94</volume><issue>1</issue><fpage>F13</fpage><lpage>F16</lpage><pub-id pub-id-type="pmid">18463119</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Lahra MM, Beeby PJ, Jeffery HE. Maternal versus fetal inflammation and respiratory distress syndrome: a 10-year hospital cohort study. Arch Dis Child Fetal Neonatal Ed. 2009;94(1):F13&#x02013;6.<pub-id pub-id-type="pmid">18463119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Abugisisa</surname><given-names>L</given-names></name><name><surname>Royse</surname><given-names>EX</given-names></name><name><surname>Kemp</surname><given-names>MW</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Hillman</surname><given-names>NH</given-names></name></person-group><article-title>Preterm ovine respiratory epithelial cell responses to mechanical ventilation, lipopolysaccharide, and interleukin-13</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2023</year><volume>324</volume><issue>6</issue><fpage>L815</fpage><lpage>L824</lpage><pub-id pub-id-type="pmid">37096911</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Abugisisa L, Royse EX, Kemp MW, Jobe AH, Hillman NH. Preterm ovine respiratory epithelial cell responses to mechanical ventilation, lipopolysaccharide, and interleukin-13. Am J Physiol Lung Cell Mol Physiol. 2023;324(6):L815&#x02013;24.<pub-id pub-id-type="pmid">37096911</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Goldenberg</surname><given-names>RL</given-names></name><name><surname>Kemp</surname><given-names>MW</given-names></name></person-group><article-title>Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks</article-title><source>Am J Obstet Gynecol</source><year>2023</year><volume>230</volume><issue>3</issue><fpage>330</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">37734637</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Jobe AH, Goldenberg RL, Kemp MW. Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks. Am J Obstet Gynecol. 2023;230(3):330&#x02013;9.<pub-id pub-id-type="pmid">37734637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Stock</surname><given-names>SJ</given-names></name><name><surname>Kemp</surname><given-names>MW</given-names></name></person-group><article-title>Antenatal steroids: Benefits, risks, and new insights</article-title><source>J Endocrinol</source><year>2023</year><volume>258</volume><issue>2</issue><fpage>e220306</fpage><pub-id pub-id-type="pmid">37130353</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Fee EL, Stock SJ, Kemp MW. Antenatal steroids: Benefits, risks, and new insights. J Endocrinol. 2023;258(2):e220306.<pub-id pub-id-type="pmid">37130353</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Fee</surname><given-names>EL</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><name><surname>Schmidt</surname><given-names>AF</given-names></name><name><surname>Usuda</surname><given-names>H</given-names></name><name><surname>Kemp</surname><given-names>MW</given-names></name></person-group><article-title>The complex challenge of antenatal steroid therapy nonresponsiveness</article-title><source>Am J Obstet Gynecol</source><year>2022</year><volume>227</volume><issue>5</issue><fpage>696</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">35932879</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Takahashi T, Jobe AH, Fee EL, Newnham JP, Schmidt AF, Usuda H, Kemp MW. The complex challenge of antenatal steroid therapy nonresponsiveness. Am J Obstet Gynecol. 2022;227(5):696&#x02013;704.<pub-id pub-id-type="pmid">35932879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Kallapur</surname><given-names>SG</given-names></name><name><surname>Kramer</surname><given-names>BW</given-names></name><name><surname>Moss</surname><given-names>TJM</given-names></name><name><surname>Newnham</surname><given-names>JP</given-names></name><name><surname>Jobe</surname><given-names>AH</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name><name><surname>Bachurski</surname><given-names>CJ</given-names></name></person-group><article-title>Maternal glucocorticoids increase endotoxin-induced lung inflammation in preterm lambs</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2003</year><volume>284</volume><issue>4</issue><fpage>L633</fpage><lpage>L642</lpage><pub-id pub-id-type="pmid">12471018</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Kallapur SG, Kramer BW, Moss TJM, Newnham JP, Jobe AH, Ikegami M, Bachurski CJ. Maternal glucocorticoids increase endotoxin-induced lung inflammation in preterm lambs. Am J Physiol Lung Cell Mol Physiol. 2003;284(4):L633&#x02013;42.<pub-id pub-id-type="pmid">12471018</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>McClure</surname><given-names>EM</given-names></name><name><surname>Colaci</surname><given-names>D</given-names></name><name><surname>Thorsten</surname><given-names>V</given-names></name><name><surname>Hibberd</surname><given-names>PL</given-names></name><name><surname>Esamai</surname><given-names>F</given-names></name><name><surname>Garces</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Saleem</surname><given-names>S</given-names></name><name><surname>Pasha</surname><given-names>O</given-names></name><etal/></person-group><article-title>The Antenatal Corticosteroids Trial (ACT): a secondary analysis to explore site differences in a multi-country trial</article-title><source>Reprod Health</source><year>2016</year><volume>13</volume><issue>1</issue><fpage>64</fpage><pub-id pub-id-type="pmid">27221319</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Klein K, McClure EM, Colaci D, Thorsten V, Hibberd PL, Esamai F, Garces A, Patel A, Saleem S, Pasha O, et al. The Antenatal Corticosteroids Trial (ACT): a secondary analysis to explore site differences in a multi-country trial. Reprod Health. 2016;13(1):64.<pub-id pub-id-type="pmid">27221319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Smolders-de Haas</surname><given-names>H</given-names></name><name><surname>Neuvel</surname><given-names>J</given-names></name><name><surname>Schmand</surname><given-names>B</given-names></name><name><surname>Treffers</surname><given-names>PE</given-names></name><name><surname>Koppe</surname><given-names>J</given-names></name><name><surname>Hoeks</surname><given-names>J</given-names></name></person-group><article-title>Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10-to 12-year follow-up</article-title><source>Pediatrics</source><year>1990</year><volume>86</volume><issue>1</issue><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">2193304</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Smolders-de Haas H, Neuvel J, Schmand B, Treffers PE, Koppe J, Hoeks J. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10-to 12-year follow-up. Pediatrics. 1990;86(1):65&#x02013;70.<pub-id pub-id-type="pmid">2193304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>RE</given-names></name><name><surname>Ramsden</surname><given-names>CA</given-names></name><name><surname>Neil</surname><given-names>HL</given-names></name><name><surname>Kyriakides</surname><given-names>MA</given-names></name><name><surname>Berger</surname><given-names>PJ</given-names></name></person-group><article-title>Volume and secretion rate of lung liquid in the final days of gestation and labour in the fetal sheep</article-title><source>J Physiol</source><year>2001</year><volume>535</volume><issue>3</issue><fpage>889</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">11559783</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Pfister RE, Ramsden CA, Neil HL, Kyriakides MA, Berger PJ. Volume and secretion rate of lung liquid in the final days of gestation and labour in the fetal sheep. J Physiol. 2001;535(3):889&#x02013;99.<pub-id pub-id-type="pmid">11559783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Wert</surname><given-names>SE</given-names></name><name><surname>Weaver</surname><given-names>TE</given-names></name></person-group><article-title>Diseases of Pulmonary Surfactant Homeostasis</article-title><source>Annu Rev Pathol</source><year>2015</year><volume>10</volume><issue>1</issue><fpage>371</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">25621661</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Whitsett JA, Wert SE, Weaver TE. Diseases of Pulmonary Surfactant Homeostasis. Annu Rev Pathol. 2015;10(1):371&#x02013;93.<pub-id pub-id-type="pmid">25621661</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Ikegami</surname><given-names>M</given-names></name><name><surname>Stahlman</surname><given-names>MT</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Ang</surname><given-names>S-L</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><article-title>Foxa2 is required for transition to air breathing at birth</article-title><source>Proc Natl Acad Sci</source><year>2004</year><volume>101</volume><issue>40</issue><fpage>14449</fpage><lpage>14454</lpage><pub-id pub-id-type="pmid">15452354</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Wan H, Xu Y, Ikegami M, Stahlman MT, Kaestner KH, Ang S-L, Whitsett JA. Foxa2 is required for transition to air breathing at birth. Proc Natl Acad Sci. 2004;101(40):14449&#x02013;54.<pub-id pub-id-type="pmid">15452354</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Moufarrej MN, Wong RJ, Shaw GM, Stevenson DK, Quake SR: Investigating Pregnancy and Its Complications Using Circulating Cell-Free RNA in Women's Blood During Gestation. Frontiers in Pediatrics 2020, Volume 8 - 2020.</mixed-citation></ref></ref-list></back></article>